

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-Segment-Elevation Acute Coronary Syndrome. A population-based cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028114
Article Type:	Research
Date Submitted by the Author:	26-Nov-2018
Complete List of Authors:	Ribera, Aida; University Hospital Vall d'Hebron, Cardiology Ferreira-Gonzalez, Ignacio; University Hospital Vall d'Hebron, Cardiology Marsal, Josep Ramon; University Hospital Vall d'Hebron, Cardiology Oristrell, Gerard; University Hospital Vall d'Hebron, Cardiology Faixedas, Maria Teresa; Servei Català de la Salut, Catalonia, Spain Rosas, Alba; 4. Departament de Salut, Generalitat de Catalunya Tizón-Marcos, Helena; 5. Cardiology Department, Hospital del Mar, and Heart Diseases Biomedical Research Group and IMIM (Hospital del Mar Medical Research Institute), and Faculty of Medicine, Universitat Autònoma de Barcelona Rojas, Sergio; 6. Cardiology Department, Hospital Universitari de Tarragona Joan XXIII, IISPV, and Universidad Rovira Virgili Labata, Carlos; Cardiology Department, Hospital German Tries i Pujol Cardenas, Merida; Cardiology Department, Hospital Josep Trueta Homs, Silvia; Cardiology Department, Hospital Mútua de Terrassa Tomas-Querol, Carlos; Cardiology Department, Hospital Arnau de Villanova Garcia-Picart, Joan; 11. Cardiology Department, Hospital de la Santa Creu i Sant Pau Gomez-Hospital, Joan; Cardiology Department, Hospital de Bellvitge Pijoan, Jose; BioCruces Health Research Institute Masotti, Monica; Cardiology Department, Hospital Clínic Mauri, Josepa; Departament de Salut, Generalitat de Catalunya Garcia Dorado, David; University Hospital Vall d'Hebron, Cardiology
Keywords:	dual antiplatelet therapy, adherence, ST-elevation myocardial infarction, percutaneous coronary intervention

SCHOLARONE™
Manuscripts

1
2
3 **Persistence with dual antiplatelet therapy after percutaneous coronary intervention**
4 **for ST-Segment-Elevation Acute Coronary Syndrome. A population-based cohort**
5 **study**
6
7
8
9

10 Aida Ribera^{1,2}, PhD; Ignacio Ferreira-González^{1,2}, MD PhD; Josep Ramon Marsal^{1,2}, Bsc;
11 Gerard Oristrell^{1,2}, MD Maria Teresa Faixedas³, MD; Alba Rosas⁴, PhD; Helena Tizón-
12 Marcos⁵, MD; Sergio Rojas⁶, MD; Carlos Labata⁷, MD; Mérida Cárdenas⁸, MD; Silvia
13 Homs⁹, MD; Carlos Tomás-Querol¹⁰, MD; Joan Garcia-Picart¹¹, MD; Joan A. Gomez-
14 Hospital¹², MD, PhD; Jose Ignacio Pijoan^{2,13}, MD PhD; Monica Masotti¹⁴, MD; Josepa
15 Mauri^{4,7}, MD PhD; David García-Dorado¹, MD PhD
16
17
18
19
20
21
22
23
24

25 On behalf of the VESA Study and Codi IAM Investigators
26

- 27 1. Cardiology Department, Vall d'Hebrón Hospital, Vall d'Hebron Research
28 Institute (VHIR) and Universitat Autònoma de Barcelona. Barcelona, Spain
29
- 30 2. CIBER de Epidemiología y Salud Pública (CIBERESP). Spain
31
- 32 3. Servei Català de la Salut, Catalonia, Spain
33
- 34 4. Departament de Salut, Generalitat de Catalunya, Catalonia, Spain.
35
- 36 5. Cardiology Department, Hospital del Mar, and Heart Diseases Biomedical
37 Research Group and IMIM (Hospital del Mar Medical Research Institute), and
38 Faculty of Medicine, Universitat Autònoma de Barcelona. Spain
39
- 40 6. Cardiology Department, Hospital Universitari de Tarragona Joan XXIII, IISPV,
41 and Universidad Rovira Virgili. Tarragona. Spain.
42
- 43 7. Cardiology Department, Hospital German Tries i Pujol. Barcelona. Spain.
44
- 45 8. Cardiology Department, Hospital Josep Trueta. Girona. Spain.
46
- 47 9. Cardiology Department, Hospital Mútua de Terrassa. Bcelona. Spain.
48
- 49 10. Cardiology Department, Hospital Arnau de Villanova. Lleida. Spain.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 11. Cardiology Department, Hospital de la Santa Creu i Sant Pau. Barcelona. Spain.
4

5 12. Cardiology Department, Hospital de Bellvitge. Barcelona. Spain
6

7
8 13. BioCruces Health Research Institute, Bilbao. Spain
9

10 14. Cardiology Department, Hospital Clínic, Barcelona. Spain.
11
12
13
14
15

16 **Corresponding author**

17
18
19 Ignacio Ferreira-González. Cardiovascular Epidemiology Unit. Cardiology Department.
20

21 University Hospital Vall d'Hebron. Psg. Vall d'Hebron, 119-129 08035 Barcelona. Spain
22

23
24 nachoferreira@secardiologia.es
25

26
27 tel. 932746177
28
29
30

31 **Word count:** 3462
32

33
34 **Keywords:** dual antiplatelet therapy, adherence, ST-elevation myocardial infarction,
35
36 percutaneous coronary intervention
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: International guidelines recommending dual antiplatelet therapy (DAPT) 12 months in patients with ST-elevation acute coronary syndrome (STEACS) undergoing percutaneous coronary intervention (PCI) were published in year 2012. The aims of the study were to describe trends in 12-month persistence with DAPT between 2010 and 2015 and to evaluate its relationship with variability in the recommended DAPT duration among PCI hospitals.

Design: Observational study based on region-wide registry data linked to pharmacy billing data for DAPT follow up.

Setting. All PCI hospitals (10) belonging to the AMI-Code network in Catalonia (Spain)

Participants: 10,711 STEACS patients undergoing PCI between 2010 and 2015 were followed up.

Primary and secondary outcome measures: Primary outcome was at least 12 month persistence with DAPT throughout the study period. 12-months recommendation of DAPT in the hospital discharge report and interhospital variability in the rate of 12-month recommendation were defined as secondary outcomes.

Results: The proportion of patients on-DAPT at 12 months increased from 58% (56-60) in 2010 to 73% (71-75) in 2015. Interhospital variability in the rate of 12-month recommendation decreased from ICC 69% (42-87) in 2010 to 37% (18-61) in 2015. Recommending 12 months DAPT at discharge from the PCI hospital was a major determinant of adherence to the 12-month schedule, OR=6.28 (5.28-7.47).

Conclusion: Adherence to 12-month DAPT has increased since publication of clinical guidelines. Even though most patients were discharged on DAPT, only 73% with potential indication were on-DAPT 12 months after PCI. A guideline-based

1
2
3 recommendation at PCI hospital discharge had a substantial impact on persistence
4
5 with DAPT. Establishing evidence-based, common prescribing criteria across hospitals
6
7
8 in the AMI-network would favour adherence and reduce variability.
9
10
11
12

13 **Strengths and limitations of this study**

- 14
15
16 • The study describes the trends in persistence with DAPT during 2010-2015 in a
17
18 region-wide unselected comprehensive cohort of patients using administrative
19
20 data linked to a clinical registry
21
22
- 23
24 • It also evaluates the impact of the DAPT duration recommended at the PCI
25
26 hospital discharge on 12-months persistence
27
28
- 29
30 • Limitations of using observational registry data include the possibility of coding
31
32 errors and the inability to accurately identify specific contraindications for
33
34 treatment or other patient characteristics that might be relevant for the study
35
36 aims
37
- 38
39 • The use of pharmacy refill data as a proxy of patients adherence and
40
41 persistence has also limitations which have been extensively described
42
43
44
45

46 **Study funding**

47
48
49 The study was supported by Instituto de Salud Carlos III grand number PI13/00399 and
50
51 the Fundació la Marató de TV3 grand number 430/U/2015. The funders did not have
52
53 any role in the study design and development.
54
55
56

57 **Competing interest statement**

1
2
3 All authors have completed the ICMJE uniform disclosure form at
4 http://www.icmje.org/coi_disclosure.pdf and declare: no support from any
5
6
7
8 organisation for the submitted work; no financial relationships with any organisations
9
10 that might have an interest in the submitted work in the previous three years, no other
11
12 relationships or activities that could appear to have influenced the submitted work
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

The need of dual antiplatelet therapy (DAPT) combining aspirin and an ADP-receptor blocker for at least 12 months in patients with ST-elevation acute coronary syndrome (STEACS) undergoing percutaneous coronary intervention (PCI) is well established and was incorporated into clinical guidelines in 2012[1,2].

Adherence of patients to this strategy is crucial to ensure its efficacy. Adherence to medication is usually defined[3] as the extent to which patients take medications as prescribed by their health care providers and persistence is defined as time from initiation to discontinuation of a therapy. Patients' persistence with DAPT may be influenced by several factors but will depend strongly on whether they ultimately receive a correct prescription from their physicians in the primary care setting. Patients may receive recommendations from various health providers at different stages of their process of care, from the interventionist cardiologist to their primary physician. It could be hypothesized that the last would tend to relay on the recommendation of the more specialized health professional. Thus, one potential determinant of patient's persistence with DAPT for at least 12 months is the instructions provided in the discharge report of the hospital where the patient was attended during the acute phase.

In Catalonia, an autonomous region of Spain, the acute care of STEACS is organized through a region-wide network, the Acute Myocardial Infarction (AMI) Code, to derive patients with suspected STEACS to one of the 10 reference hospitals with PCI capability. Performance of the AMI Code is prospectively and exhaustively registered[4,5], providing an appropriate tool for quality evaluation. The Catalan

1
2
3 Health Information System systematically registers, among other, data on pharmacy
4 refills. Pharmacy billing data, although indirect, is an accepted method for evaluating
5 persistence with treatment in large patient cohorts[3,6].
6
7
8
9

10 The aims of the present study were: first, to describe persistence with DAPT in patients
11 with STEACS undergoing PCI from 2010 to 2015; second, to evaluate the impact of the
12 DAPT duration recommended at the PCI hospital discharge on patients' persistence
13 with treatment for at least 12 months as recommended in clinical guidelines. As a main
14 determinant of persistence, determinants and variability of discharge recommendation
15 patterns will be also analysed as a secondary objective.
16
17
18
19
20
21
22
23
24
25
26

27 **Methods**

28 *Data sources*

29
30
31 Data were obtained through the Public Data Analysis for Health Research and
32 Innovation Program (PADRIS). The PADRIS allows access to information from different
33 sources on public healthcare usage for the population of Catalonia linked at the
34 patient level with warranted accomplishment of ethical principles. Specifically, for the
35 present study we linked data of the pharmacy billing registry with the AMI Code
36 Registry. The AMI Code registry was launched in 2010 to evaluate performance of the
37 AMI Code [4,5]. Exhaustiveness and quality of data is assessed periodically (see
38 supplemental methods for details). The database belongs to the Catalan Department
39 of Health and includes demographic, clinical, and therapeutic data. It conforms to the
40 ethical and legal requirements for research purposes. The study obtained ethics
41 approval from the Vall d'Hebron Clinical Research Ethics Committee.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The registry was completed for the purpose of the present analysis with retrospective
4 collection of additional specific data: diseased vessels, responsible vessel, stent type,
5
6 number of stents. The recommendation of antithrombotic drugs was also collected *ad*
7
8 *hoc* for the study from the discharge report. The recommendation of DAPT was
9
10 defined as the recommendation of Acetylsalicylic acid (ASA) and either clopidogrel,
11
12 prasugrel or ticagrelor for specified periods. If the recommended duration of DAPT was
13
14 not specified, the discharge recommendation pattern was classified as “unspecified”. A
15
16 local investigator at each center performed the specific retrospective data collection.
17
18 History of major haemorrhage, neoplasia, renal disease, heart failure, peripheral
19
20 arterial disease and atrial fibrillation, were obtained from minimum basic data set
21
22 (MBDS) diagnoses coded in hospitalization episodes occurring in the previous three
23
24 months before index hospitalization. Major haemorrhage was defined as: a diagnosis
25
26 of digestive bleeding in any diagnostic position (primary or secondary) together with a
27
28 procedure code for endoscopic treatment or for transfusion of blood products, or a
29
30 diagnosis of haemorrhagic stroke, or a diagnosis of intraocular haemorrhage, or a
31
32 diagnosis of other types of haemorrhage together with a procedure code for
33
34 transfusion of blood products. Major ischemic events (AMI or stroke) and major
35
36 haemorrhage during the 12 months following the index episode were obtained in the
37
38 same way. Mortality during the 12 months following the index episode was obtained
39
40 from the insured registry status.
41
42
43
44
45
46
47
48
49
50

51
52
53 Drug treatment during the 12-month post-discharge follow up was obtained from the
54
55 pharmacy billing registry. ICD9 and ATC codes used for the identification of study
56
57 variables are listed in the supplemental tables.
58
59
60

Study population

All consecutive patients who survived a STEACS between January 2010 and December 2015, received primary or post fibrinolysis PCI in one of the 10 reference hospitals of the AMI Code network and were discharged alive and/or survived at least one month after AMI with a discharge report providing instructions on treatment prescriptions were included. New episodes of STACS occurring to the same patients during the study period were only accounted as follow up events. Patients with likely contraindication for dual antiplatelet therapy (history of bleeding or neoplasm in the three months prior to the index episode and patients requiring anticoagulation) were excluded.

Persistence with treatment

DAPT was defined as the concomitant use of ASA and a P2Y₁₂ antagonist. Persistence with DAPT was estimated by identification of consecutive months with pharmacy refills with one container of each agent in the 12-month period after hospital discharge. Because pharmacy billing is registered in a monthly basis and the exact day of dispensation is unknown, we considered that a monthly dispensation until at least month 11 after the index episode would approximate a 12-months treatment period. If more than one container were dispensed in one month, the excess containers were pulled along the following months. Non-persistence was defined as either discontinuation or a break in therapy of at least two months after pulling along the excess containers. To describe persistence over the whole study period we estimated the proportion of patients alive who were on treatment on each month[7].

1
2
3 The first primary outcome was a patients' persistence with DAPT for 12 months
4 following discharge (or in other words, patients withdrawing both agents from the
5 pharmacy until at least month 11).
6
7
8
9

10 11 12 ***Statistical analysis***

13
14
15 To evaluate trends in 12 months persistence with DAPT we included the calendar year
16 when the patient was discharged in logistic regression models. To evaluate the impact
17 of the DAPT duration recommended in the discharge report, we included the
18 recommendation pattern (≤ 1 month, 2 to 11 months, ≥ 12 months or unspecified) in a
19 second step.
20
21
22
23
24
25
26

27 Additionally, we assessed the determinants (including calendar year of the episode) of
28 a DAPT recommendation for at least 12 months with logistic regression models.
29
30
31

32 In both sets of analyses we took into account the clustered structure of data with
33 patients being treated and, most importantly, with medications being recommended
34 in different hospitals, by introducing random effects in the logistic regression models.
35
36
37
38

39 As recommendation is subject to interhospital variability we estimated variability
40 measures for random effects. We tested whether models including random intercept
41 for hospital and random slopes for each independent variable were significant using a
42 deviance –based test of hypothesis.
43
44
45
46
47
48

49 Variable selection for multilevel modelling was based on the bivariate associations
50 with the rate of each dependent variable. Candidate individual variables were those
51 described in tables 1 and 3. Type of antiplatelet drug was not included in the
52 multivariable analysis because it was highly correlated with the year of episode, as new
53 antiplatelet agents (ticagrelor and prasugrel) were introduced later during the study
54
55
56
57
58
59
60

1
2
3 period. We retained in the final model all variables with a p value<0.2 for the bivariate
4
5 association with the dependent variable.
6
7

8 To measure the magnitude of hospital level variance in the odds of patients being
9
10 recommended DAPT for at least 12 months we estimated the intraclass correlation
11
12 (ICC) and the median odds ratio (MOR) for multilevel logistic models. The ICC can be
13
14 interpreted as the proportion of total variance in the outcome that is attributable to
15
16 the hospital level variability. The MOR is defined as the median value of the odds ratio
17
18 between the hospital at higher risk and the hospital at lower risk when randomly
19
20 picking out two hospitals. In the present study, the MOR estimates the extent to which
21
22 the individual odds of being recommended DAPT for 12 months is determined by the
23
24 hospital where the procedure is performed. If the MOR equals one, there would be no
25
26 differences between hospitals. If the MOR is large, hospital differences are relevant to
27
28 understand variations in individual probability of receiving a 12-month
29
30 recommendation.
31
32
33
34
35

36
37 Multilevel logistic regression models were estimated assuming independent
38
39 covariances using the xtmelogit procedure in STATA 14. Methods and formulas to
40
41 compute indexes of interhospital variability and different measures of clustering were
42
43 obtained from Merlo et al[8].
44
45
46
47
48

49 ***Sensitivity analyses***

50
51 As a substantial proportion of patients were returned to their reference hospital and
52
53 whether the DAPT duration recommendation was changed at discharge from the
54
55 second hospital was unknown, we performed sensitivity analyses excluding these
56
57 patients. Additionally, because ischemic and haemorrhagic events occurring during
58
59
60

1
2
3 follow up would change the prescription pattern, sensitivity analyses were also
4
5 performed by excluding patients suffering any vascular event during follow up.
6
7
8
9

10 **Results**

11
12 After excluding patients with likely contraindication for, we identified 10,711 STEACS
13
14 patients undergoing PCI who were potential candidates to receive DAPT for at least 12
15
16 months and were discharged alive from the PCI hospitals or survived for at least one
17
18 month (Figure 1). 631 (5.9%) patients experienced an ischemic major event (AMI or
19
20 stroke) within 12 months after the index episode, 100 (0.9%) had a major
21
22 haemorrhage and 280 (2.6%) died between one and 12 months after the index
23
24 episode.
25
26
27
28

29
30 The rate of patients on-DAPT after discharge was 91% (95% CI: 90-91) without relevant
31
32 differences between years (figure 2). Persistence with DAPT for 12 months significantly
33
34 increased from 58% (56-61) in 2010 to 73% (71-75) in 2015. The larger increase in 12-
35
36 month persistence was observed between 2014 (64% [62-66]) and 2015, two years
37
38 after the publication of clinical guidelines. There was a growing rate of prasugrel and
39
40 ticagrelor dispensation along the study period (figure 3).
41
42
43
44

45 Table 1 shows characteristics of study patients depending on persistence with DAPT
46
47 for one month or less, 2 to 11 months or 12 months or more. The majority (76%) of
48
49 patients (4740/6272) with an explicit recommendation of 12 months DAPT or more at
50
51 PCI hospital discharge were on-DAPT at 12 months. This proportion was only 27%
52
53 (462/1735) in the subgroup of patients with a shorter recommended duration. Among
54
55 patients without a specified recommended time at discharge from the PCI hospital,
56
57 60% (1399/2332) were on-DAPT at 12 months. In multivariate analysis (Table 2),
58
59
60

1
2
3 determinants of persistence with DAPT for at least 12 months were
4
5 hypercholesterolemia, previous revascularization, having two or more diseased vessels
6
7 and left anterior coronary disease, higher number of stents implanted and receiving
8
9 drug eluting stents. An increased odd of persistence was observed in year 2015 but
10
11 this association disappeared when including the prescription pattern. A longer
12
13 hospital stay was related to a lower probability of 12 months persistence with DAPT.
14
15 As expected, having an ischaemic event would increase DAPT duration, while suffering
16
17 a haemorrhagic event would decrease it. Explicit instructions at the discharge report
18
19 of DAPT for at least 12 months was one of the major determinants of 12-month
20
21 persistence (OR=6.28; 95%CI: 5.28-7.47), and also patients with unspecified
22
23 recommendation had an increased odds of persistence as compared with patients with
24
25 a recommendation of less than 12 months.
26
27
28
29
30

31
32 Results of sensitivity analyses, excluding patients with ischemic or haemorrhagic
33
34 events during follow up, or excluding patients that were transferred to another centre
35
36 after PCI were similar to the main analysis.
37
38
39

40 The rate of explicit DAPT recommendation for at least 12 months in the hospital
41
42 discharge reports was 51% (49-53) in 2010 and increased to 77% (75-79) in 2015
43
44 (supplemental figure). Interhospital variability in the rate of 12-month DAPT
45
46 recommendation (figure 3) was 69% (42-87) in year 2010, indicating that half of the
47
48 variability was due to variation between hospitals, and it decreased to 37% (18-61) in
49
50 2015, as indicated by the ICC calculated for each year.
51
52
53

54 Table 3 shows characteristics of study patients depending on the DAPT duration
55
56 recommended at hospital discharge. In multivariate analysis (table 4) the strongest
57
58 determinant of a higher rate of recommendation for ≥ 12 months was receiving a drug
59
60

1
2
3 eluting stent. Other determinants were. There was also a strong increase in the rate of
4
5 12 months prescription in with year. For both random effect were significant, meaning
6
7 that the association with drug eluting stent or with year vary between hospitals. When
8
9 patients derived to their reference hospital were excluded results were similar.
10
11
12
13
14

15 **Discussion**

16
17 According to published guidelines, all STEACS patients undergoing PCI without
18
19 contraindication should be on DAPT after 12 months unless an event occurs that
20
21 precludes continuing with treatment. In this observational region-wide study we have
22
23 found an increase in the proportion of patients on-DAPT at 12 months from 58 to 73%
24
25 in the period from 2010 to 2015.
26
27
28

29
30 We also found a high variability between hospitals in the adherence to guidelines
31
32 when recommending DAPT for at least 12 months which leads to differences between
33
34 hospitals in the rate of patients persisting with the recommended DAPT one year time
35
36 span. The progressive increase in the overall rate of adherence to guidelines was
37
38 accompanied by a substantial reduction of interhospital variability.
39
40

41
42 Adherence of patients to 12-month DAPT assessed is strongly related to the
43
44 instructions given at the PCI hospital discharge, as we observed a lower rate of 12-
45
46 month persistence in patients receiving a discharge DAPT recommendation for less
47
48 than 12 months. Although a causal direct relationship between the established
49
50 recommendation in the more specialised setting and the final prescription at the
51
52 primary care setting cannot be stated on the basis of observational data, this finding
53
54 suggests that prescribing physicians strongly rely on the first recommendation
55
56 specified at the discharge report in the PCI hospital. Therefore, hospital cardiologists
57
58
59
60

1
2
3 should be kept aware of their impact and encouraged to be clear and specific enough
4
5 when providing DAPT time recommendations in the discharge report form.
6
7

8 A number of factors have been described to contribute to underprescription[9]. The
9
10 recommendation of DAPT for at least 12 months following STEACS[1,2] was based on
11
12 the duration of follow up of randomised clinical trials designed for other purposes
13
14 and[10–12], although a 12-month treatment seemed reasonable [13], no randomized
15
16 studies have been performed to date aimed specifically at comparing 12 months DAPT
17
18 with shorter in STEACS patients receiving PCI and thus this recommendation might well
19
20 be seen as somehow arbitrary by some prescribers.
21
22
23

24
25 In 2015 the need for long term DAPT was reinforced by the recommendation of
26
27 extended DAPT beyond 12 months in patients with ACS receiving drug eluting
28
29 stents[14–16], but still safety concerns might induce some prescribers to be reluctant
30
31 to prolong DAPT, especially in patients with higher complexity[17]. Safety concerns
32
33 might also explain the high proportion of discharge reports with non-specified DAPT
34
35 period, which deserved special attention in our analyses. Cardiologists might be
36
37 reluctant to prescribe a specific duration of DAPT maybe fearing about the emergency
38
39 of events that increase the haemorrhagic risk at some point after discharge, thus
40
41 relaying on the follow up that will be made at the ambulatory setting. Our results
42
43 showing a high degree of persistence for patients without a specification of DAPT time
44
45 point out to the fact that this decision is not necessarily “incorrect”, and that health
46
47 providers coming later in the process of care are probably doing their job.
48
49
50
51
52
53

54 We might wonder whether the observed high variability between hospitals in the
55
56 instructions provided about DAPT duration actually reflects suboptimal quality of care
57
58 or confusion in the interpretation of international guidelines. In fact, although 2012
59
60

1
2
3 ESC guidelines state that DAPT must be continued for 12 months after STEACS with a
4 class of recommendation I, the level of evidence was established as C[1]. Thus, there
5
6 was general agreement that a minimum of 12 months of DAPT is beneficial but based
7
8 only on a consensus of experts or observational studies. Moreover, it is literally stated
9
10 that the given recommendation on DAPT duration should be “with a strict minimum of
11
12
13 1 month for patients receiving BMS and 6 months for patients receiving DES”, with
14
15 Class IC and IIb respectively. This, which ultimately reflects the lack of clinical trials
16
17 aimed to answer the specific question about DAPT duration, could have induced a
18
19 perception of arbitrariness leading to variability in clinical practice.
20
21
22
23

24
25 Regardless the level of the evidence, one would expect that a Class I recommendation
26
27 should be uniformly followed by clinicians. Moreover, as patient characteristics did not
28
29 substantially differed across hospitals, we should expect a lower variability between
30
31 hospitals. A large variation in individual country practices concerning the pattern of
32
33 DAPT duration after ACS has been described, suggesting that local systems are strong
34
35 drivers of DAPT duration[18]. These findings may imply that there is still room for
36
37 improvement in the quality of care of STEACS patients and that quality improvement
38
39 programs, whose efficacy and cost-effectiveness are still under evaluation, could be
40
41 useful to reduce variability in clinical practice[19]. This is of prime importance in the
42
43 context of the prescription of DAPT duration after ACS in which the clinician-driven
44
45 variability in prescription patterns adds to the different levels patients’ adherence[18].
46
47
48
49
50
51 Higher atherosclerotic burden and increased ischemic risk was associated to better
52
53 persistence with DAPT. The need for 12-month DAPT schedules in patients treated
54
55 with drug eluting stents is clearly perceived by physicians but the magnitude of this
56
57 association varies largely between hospitals. This means that, even in clear indications,
58
59
60

1
2
3 there are different levels of adoption of emerging clinical recommendations in
4
5 hospitals belonging to the same AMI network.
6
7

8 It is also apparent from our data that the speed of adoption of clinical guidelines is
9
10 different among hospitals and that an acceptable and generalised level of adherence is
11
12 only reached after two years of implementation. Similar trends have been found in
13
14 other contexts and earlier periods[20–25] reporting DAPT use between 60-80% at
15
16 discharge and between 25-75 % at one year. In this sense, together with other quality
17
18 improvement initiatives, the use of population-based registries to provide audit and
19
20 feedback could be useful to promote quicker and smoother adoption of clinical
21
22 practice guidelines[26].
23
24
25
26
27
28
29

30 There are a number of assumptions that might be questionable: The complete process
31
32 of care and the definite prescription at the ambulatory setting is poorly known for
33
34 individual patients and has not been considered in this study. Changes in treatment
35
36 prescription might be justified by the patients' varying conditions during follow up. We
37
38 assume that hospital recommendation influences final prescription, and consequently,
39
40 final adherence, but it can also be that both "prescribers" facing the same patient
41
42 share the same criteria for prescription. I.e. the hospital cardiologist might have
43
44 decided to recommend DAPT for a shorter period to an elderly patient with other
45
46 comorbidities and suboptimal quality of life due to mild digestive symptoms, even if
47
48 her objective bleeding risk is not high; similarly, the primary physician or the
49
50 cardiologist at the primary care setting might have also decided to be less aggressive
51
52 for the same reasons, even without being influenced by the recommendation of the
53
54 first. This would probably explain a large amount of the strong relationship between
55
56
57
58
59
60

1
2
3 hospital recommendation and pharmacy dispensation. Moreover, although effects
4
5 were adjusted for patient characteristics and vascular events during follow up, there
6
7 might be other unmeasured reasons for deciding upon a shorter DAPT period facing an
8
9 individual patient.
10
11

12
13 In addition, the recommendation at PCI hospital discharge may not coincide with the
14
15 final hospital prescription in patients derived to another reference hospital after PCI.
16
17 However, results of sensitivity analyses excluding these patients did not differ
18
19 substantially from the results of the main analyses.
20
21

22
23 The study was aimed to ascertain adherence to guidelines in hospital recommendation
24
25 and its impact on patients' persistence with DAPT and thus, we did not measure the
26
27 impact of adherence in terms of clinically relevant results which will be analysed
28
29 further. Similarly, the study was not specifically aimed at a deep assessment of
30
31 determinants of adherence. This requires a detailed examination of the social context
32
33 and a detailed assessment of individual psychological factors[27].
34
35
36
37
38
39

40 **Conclusion**

41
42 From 2010 to 2015 there has been a substantial increase in the rate of STEACS patients
43
44 persisting for at least 12 months has also increased but there is still a large variability
45
46 between hospitals in prescription and a substantial proportion of patients who
47
48 discontinue DAPT before 12 months.
49

50
51 We have shown that instructions given at the PCI hospital discharge strongly influence
52
53 persistence, thus establishing common and rational prescribing criteria between
54
55 hospitals in the STEACS-network may favour patients adherence and persistence with
56
57 scheduled prescriptions and also reduce variability in clinicians' practices.
58
59
60

Author contributions

IFG, AR, JRM conceived and designed the study; AR, JRM and MTF participated in the acquisition and analysis of data; HTM, SR, CL, MC, SH, CTQ, JGP, JAGH and MM were responsible for data acquisition in their respective hospitals; AR, IFG, JRM, GO, AR, JIP, JM and DGD were involved in the interpretation of results; AR and IFG wrote the manuscript and all other authors revised it critically and approved its final version

The AMI-Code Registry Investigators (listed below) contribute to the functioning of the AMI code and to data acquisition for the AMI-Code Registry:

C. Carvajal, P. Martínez, RM. Lidón, J. Bañeras (Hospital Universitari de la Vall d'Hebrón, Barcelona), J. Garcia-Picart (Hospital de la Santa Creu i Sant Pau, Barcelona), M. Massotti, G. Jiménez, M. Hernández, A. Regueiro (Hospital Clinic, Barcelona), J. Basaganyas, P. Loma, M. Cardenas, E. Badosa, A. Fageda (Hospital Josep Trueta, Girona) A. Ariza, C. García-Amigó, A. Cequier, A. Gómez-Hospital, G. Marín, J. Maristany, V. Montoya (Hospital Universitari de Bellvitge, Hospitalet) , C. Labata, J. Mauri, E. Fernández-Nofrerias, X. Carrillo, C. Garcia-Garcia, C. Oliete, (Hospital Universitari Germans Trias i Pujol, Badalona) A. Bardaji, G. Bonet-Pineda, S. Rojas (Hospital Joan XXIII, Tarragona). Juan F. Muñoz, F. Padilla, S. Homs (Hospital Mútua de Terrassa, Terrassa), B. Baquerizo, L. Recasens, H. Tizon-Marcos (Hospital de Mar IMAS, Barcelona), A. Bosch Gaya, F. Worner, L. Barta, M. Agustí, A. Gené (Hospital Arnau de Vilanova, Lleida), X. Jimenez, A. Mora (Sistema d'Emergencies Mèdiques SEM SA,

1
2
3 Barcelona), MT. Faixedas, J. Jiménez, A. Rosas (Health Department. Generalitat de
4
5 Catalunya).
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

- 1 Steg PG, James SK, Atar D, *et al.* ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). *Eur Heart J* 2012;**33**:2569–619. doi:10.1093/eurheartj/ehs215
- 2 O’Gara PT, Kushner FG, Ascheim DD, *et al.* 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;**127**:e362–425. doi:10.1161/CIR.0b013e3182742cf6
- 3 Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med* 2005;**353**:487–97. doi:10.1056/NEJMra050100
- 4 Carrillo X, Fernandez-Nofrerias E, Rodriguez-Leor O, *et al.* Early ST elevation myocardial infarction in non-capable percutaneous coronary intervention centres: *in situ* fibrinolysis vs. percutaneous coronary intervention transfer. *Eur Heart J* 2016;**37**:1034–40. doi:10.1093/eurheartj/ehv619
- 5 Regueiro A, Bosch J, Martín-Yuste V, *et al.* Cost-effectiveness of a European ST-segment elevation myocardial infarction network: results from the Catalan Codi Infart network. *BMJ Open* 2015;**5**:e009148. doi:10.1136/bmjopen-2015-009148
- 6 Swieczkowski D, Mogielnicki M, Cwalina N, *et al.* Medication adherence in patients after percutaneous coronary intervention due to acute myocardial infarction: From research to clinical implications. *Cardiol J* 2016;**23**:483–90.

- 1
2
3 doi:10.5603/CJ.a2016.0048
4
5
6 7 Gislason GH, Rasmussen JN, Abildstrøm SZ, *et al.* Long-term compliance with
7
8 beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute
9
10 myocardial infarction. *Eur Heart J* 2006;**27**:1153–8.
11
12 doi:10.1093/eurheartj/ehi705
13
14
15 8 Merlo J, Chaix B, Ohlsson H, *et al.* A brief conceptual tutorial of multilevel
16
17 analysis in social epidemiology: Using measures of clustering in multilevel
18
19 logistic regression to investigate contextual phenomena. *J Epidemiol Community*
20
21 *Health*. 2006;**60**:290–7. doi:10.1136/jech.2004.029454
22
23
24
25 9 Cabana MD, Rand CS, Powe NR, *et al.* Why don't physicians follow clinical
26
27 practice guidelines? A framework for improvement. *JAMA* 1999;**282**:1458–
28
29 65.<http://www.ncbi.nlm.nih.gov/pubmed/10535437> (accessed 28 Nov 2017).
30
31
32 10 Yusuf S, Zhao F, Mehta SR, *et al.* Effects of Clopidogrel in Addition to Aspirin in
33
34 Patients with Acute Coronary Syndromes without ST-Segment Elevation. *N Engl J*
35
36 *Med* 2001;**345**:494–502. doi:10.1056/NEJMoa010746
37
38
39
40 11 Wiviott SD, Braunwald E, McCabe CH, *et al.* Prasugrel versus Clopidogrel in
41
42 Patients with Acute Coronary Syndromes. *N Engl J Med* 2007;**357**:2001–15.
43
44 doi:10.1056/NEJMoa0706482
45
46
47 12 Wallentin L, Becker RC, Budaj A, *et al.* Ticagrelor versus Clopidogrel in Patients
48
49 with Acute Coronary Syndromes. *N Engl J Med* 2009;**361**:1045–57.
50
51 doi:10.1056/NEJMoa0904327
52
53
54 13 Eisenstein EL, Anstrom KJ, Kong DF, *et al.* Clopidogrel Use and Long-term Clinical
55
56 Outcomes After Drug-Eluting Stent Implantation. *JAMA* 2007;**297**:159.
57
58 doi:10.1001/jama.297.2.joc60179
59
60

- 1
2
3 14 Bonaca MP, Bhatt DL, Cohen M, *et al.* Long-Term Use of Ticagrelor in Patients
4 with Prior Myocardial Infarction. *N Engl J Med* 2015;**372**:1791–800.
5
6 doi:10.1056/NEJMoa1500857
7
8
9
10 15 Mauri L, Kereiakes DJ, Yeh RW, *et al.* Twelve or 30 Months of Dual Antiplatelet
11 Therapy after Drug-Eluting Stents. *N Engl J Med* 2014;**371**:2155–66.
12
13 doi:10.1056/NEJMoa1409312
14
15
16
17 16 Levine GN, Bates ER, Bittl JA, *et al.* 2016 ACC/AHA Guideline Focused Update on
18 Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease:
19 A Report of the American College of Cardiology/American Heart Association
20 Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2016;**68**:1082–115.
21
22 doi:10.1016/j.jacc.2016.03.513
23
24
25
26
27
28
29
30 17 Tinetti ME, Bogardus ST, Agostini J V. Potential Pitfalls of Disease-Specific
31 Guidelines for Patients with Multiple Conditions. *N Engl J Med* 2004;**351**:2870–
32
33 4. doi:10.1056/NEJMs042458
34
35
36
37 18 Bueno H, Pocock S, Danchin N, *et al.* International patterns of dual antiplatelet
38 therapy duration after acute coronary syndromes. *Heart* 2017;**103**:132–8.
39
40 doi:10.1136/heartjnl-2016-309509
41
42
43
44
45 19 Flather MD, Babalis D, Booth J, *et al.* Cluster-randomized trial to evaluate the
46 effects of a quality improvement program on management of non–ST-elevation
47 acute coronary syndromes: The European Quality Improvement Programme for
48 Acute Coronary Syndromes (EQUIP-ACS). *Am Heart J* 2011;**162**:700–707.e1.
49
50 doi:10.1016/j.ahj.2011.07.027
51
52
53
54
55
56
57 20 Czarny MJ, Nathan AS, Yeh RW, *et al.* Adherence to Dual Antiplatelet Therapy
58 After Coronary Stenting: A Systematic Review. *Clin Cardiol* 2014;**37**:505–13.
59
60

- 1
2
3 doi:10.1002/clc.22289
4
5
6 21 Green A, Pottegård A, Broe A, *et al.* Initiation and persistence with dual
7
8 antiplatelet therapy after acute myocardial infarction: A Danish nationwide
9
10 population-based cohort study. *BMJ Open* 2016;**6**. doi:10.1136/bmjopen-2015-
11
12 010880
13
14
15 22 Anastasius M, Lau JK, Hyun K, *et al.* The underutilisation of dual antiplatelet
16
17 therapy in acute coronary syndrome. *Int J Cardiol* 2017;**240**:30–6.
18
19 doi:10.1016/j.ijcard.2017.04.077
20
21
22 23 Prami T, Khanfir H, Deleskog A, *et al.* Clinical factors associated with initiation of
23
24 and persistence with ADP receptor-inhibiting oral antiplatelet treatment after
25
26 acute coronary syndrome: a nationwide cohort study from Finland. *BMJ Open*
27
28 2016;**6**:e012604. doi:10.1136/bmjopen-2016-012604
29
30
31
32 24 Varenhorst C, Jensevik K, Jernberg T, *et al.* Duration of dual antiplatelet
33
34 treatment with clopidogrel and aspirin in patients with acute coronary
35
36 syndrome. *Eur Heart J* 2014;**35**:969–78. doi:10.1093/eurheartj/eh438
37
38
39
40 25 Chung S-C, Sundström J, Gale CP, *et al.* Comparison of hospital variation in acute
41
42 myocardial infarction care and outcome between Sweden and United Kingdom:
43
44 population based cohort study using nationwide clinical registries. *Br Med J*
45
46 2015;**351**:h3913. doi:10.1136/BMJ.H3913
47
48
49
50 26 Eisenstein EL, Wojdyla D, Anstrom KJ, *et al.* Evaluating the impact of public
51
52 health notification: Duke clopidogrel experience. *Circ Cardiovasc Qual Outcomes*
53
54 2012;**5**:767–74. doi:10.1161/CIRCOUTCOMES.111.963330
55
56
57 27 Ferreira-Gonzalez I, Marsal JR, Ribera A, *et al.* Background, Incidence, and
58
59 Predictors of Antiplatelet Therapy Discontinuation During the First Year After
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Drug-Eluting Stent Implantation. *Circulation* 2010;**122**:1017–25.

doi:10.1161/CIRCULATIONAHA.110.938290

For peer review only

Figure legends

Figure 1. Patients flow

Figure 2. Persistence with DAPT from discharge to 12 months by year of the episode.

Figure 3. Temporal trend of interhospital variability in 12 months DAPT

recommendation at the PCI hospital, measured as the percentage of variance

explained by the hospital level (intraclass correlation and 95 % CI). Vertical dashed line

indicates publication of guidelines.

Table 1. Characteristics of study patients according to DAPT persistence during follow up in patients surviving for 12 months.

	No DAPT or ≤ 1 month (n=1692)	DAPT 2-11 months (n=2037)	DAPT ≥ 12 months (n=6610)	P for trend
Patient Characteristics				
Age, mean (SD)	61.2 (13.4)	61.2 (13.1)	61.2 (12.4)	0.693
Women	362 (21.4)	421 (20.7)	1325 (20.1)	0.202
Weight*(1154 missing)	77.5 (13.4)	78.5 (14.1)	78.5 (13.8)	0.023
Cardiovascular risk factors				
Current smoker	814 (48.1)	970 (47.6)	3057 (46.3)	0.077
Diabetes mellitus	295 (17.4)	360 (17.7)	1303 (19.7)	0.011
Hypercholesterolemia	589 (34.8)	713 (35)	2690 (40.7)	<0.001
Hypertension	724 (42.8)	912 (44.8)	3158 (47.8)	<0.001
History				
Chronic Hepatic Disease	23 (1.4)	25 (1.2)	56 (0.9)	0.025
Previous acute myocardial infarction	114 (6.7)	157 (7.7)	576 (8.7)	0.005

1	Stroke or transient				
2		50 (3)	51 (2.5)	172 (2.6)	0.526
3	ischemic attack				
4					
5					
6	Previous percutaneous				
7		77 (4.6)	120 (5.9)	487 (7.4)	<0.001
8	revascularization				
9					
10					
11	Previous surgical				
12		6 (0.4)	15 (0.7)	86 (1.3)	<0.001
13	revascularization				
14					
15					
16					
17	Chronic renal				
18		77 (4.6)	110 (5.4)	320 (4.8)	0.913
19	impairment				
20					
21					
22					
23	Previous diagnosis of				
24		116 (6.9)	157 (7.7)	585 (8.9)	0.004
25	chronic heart failure				
26					
27					
28					
29	Previous diagnosis of				
30		65 (3.8)	88 (4.3)	276 (4.3)	0.913
31	peripheral arterial				
32	disease				
33					
34					
35	Previous antiplatelet				
36		228 (13.5)	303 (14.9)	1034 (15.6)	0.026
37	treatment				
38					
39					
40					
41					
42					
43	Two or more diseased				
44	vessels	578 (34.2)	706 (34.7)	2742 (41.5)	<0.001
45					
46					
47					
48					
49	Vessel responsible				
50					
51					
52	Left anterior				
53	coronary artery	601 (35.5)	737 (36.2)	2882 (43.6)	<0.001
54					
55					
56					
57					
58	Right coronary artery	710 (42)	889 (43.6)	2513 (38)	<0.001
59					
60					

1	Circumflex coronary				
2		229 (13.5)	281 (13.8)	843 (12.8)	0.256
3	artery				
4					
5					
6	Left main Coronary				
7		13 (0.8)	8 (0.4)	59 (0.9)	0.240
8	artery				
9					
10					
11					
12	No. of treated vessels				
13		1.01 (0.2)	1.04 (0.2)	1.06 (0.3)	<0.001
14	per patient, mean (SD)				
15					
16					
17	Stent				
18		1458 (86.2)	1889 (92.7)	6208 (93.9)	<0.001
19					
20					
21	Bare metal	1255 (74.2)	1542 (75.7)	3651 (55.2)	<0.001
22					
23					
24	Drug-eluting	211 (12.5)	364 (17.9)	2716 (41.1)	<0.001
25					
26					
27					
28	No. of stents per				
29		1.04 (0.6)	1.12 (0.6)	1.20 (0.7)	<0.001
30	patient, mean (SD)				
31					
32					
33					
34	Admission Features				
35					
36					
37	Admission days; mean				
38	(SD); (676 missing	8.2 (10.8)	6.9 (6)	6.7 (5.1)	0.004
39	values)				
40					
41					
42					
43					
44					
45	Discharged home from				
46	the PCI* hospital	1128 (66.7)	1132 (55.6)	3686 (55.8)	<0.001
47					
48					
49					
50					
51	DAPT† duration prescribed at PCI hospital discharge				
52					
53					
54	No DAPT or ≤1				
55	month	561 (33.2)	316 (15.5)	298 (4.5)	<0.001
56					
57					
58					
59					
60					

1	2-11 months	172 (10.2)	215 (10.6)	173 (2.6)
2				
3				
4	≥ 12 months	537 (31.7)	995 (48.9.9)	4740 (71.7)
5				
6				
7	Unspecified	422 (24.9)	511 (25.1)	1399 (21.2)
8				
9				

10
11 All numbers indicate n (column percentages) unless otherwise stated. *PCI: percutaneous coronary
12
13 intervention; †DAPT: dual antiplatelet therapy
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 2. Determinants of 12 month persistence with DAPT in patients surviving for 12 months.

	Model 1	Model 2	Model 3	Model 4
	N=10,412	N= 10,412	N=9,740	N=5,947
	N centers = 10	N centers = 10	N centers = 10	N centers = 10
Obs per center:	1041 (360-	1041 (360-	974, (330-	595 (153-
average (min-max)	2290)	2290)	2136)	1076)
Hypercholesterolemia	1.20 (1.10- 1.32)	1.21 (1.10- 1.33)	1.23 (1.12- 1.36)	1.15 (1.01- 1.31)
Previous revascularization	1.26 (1.05- 1.51)	1.22 (1.02- 1.46)	1.25 (1.04- 1.52)	1.54 (1.19- 2.00)
Two or more diseased vessels	1.21 (1.11- 1.33)	1.19 (1.08- 1.30)	1.17 (1.06- 1.29)	1.15 (1.01- 1.31)
Left anterior coronary artery	1.13 (1.03- 1.24)	1.12 (1.02- 1.23)	1.14 (1.04- 1.26)	1.04 (0.92- 1.19)
Drug eluting stent	3.21 (2.88- 3.59)	2.17 (1.93- 2.43)	2.21 (1.96- 2.49)	2.11 (1.80- 2.47)
Number of stents	1.19 (1.11- 1.28)	1.24 (1.15- 1.33)	1.26 (1.16- 1.36)	1.37 (1.24- 1.51)
Discharged home	0.86 (0.77-	0.95 (0.87-	0.93 (0.85-	N/A

	0.93)	1.05)	1.03)	
Hospital stay (for each day increase)	0.98 (0.97- 0.99)	0.98 (0.97- 0.99)	0.98 (0.97- 0.99)	0.98 (0.97- 0.98)
Ischaemic event in follow up	2.15 (1.74- 2.66)	2.33 (1.87- 2.90)	N/A	3.45 (2.47- 4.80)
Hemorrhagic event in follow up	0.42 (0.26- 0.67)	0.38 (0.24- 0.62)	N/A	0.24 (0.17- 0.34)

DAPT duration
recommended

No DAPT* or ≤ 1 month		1 (ref.)	1 (ref.)	1 (ref.)
1-11 months		1.24 (0.97- 1.59)	1.26 (0.97- 1.63)	1.81 (1.32- 2.50)
≥12 months		6.28 (5.28- 7.47)	6.54 (5.45- 7.84)	8.41 (6.68- 10.58)
unspecified		3.38 (2.84- 4.02)	3.54 (2.95- 4.24)	4.07 (3.20- 5.17)

Year

2010	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)
2011	0.90 (0.77- 1.04)	0.80 (0.68- 0.94)	0.78 (0.67- 0.92)	0.89 (0.72- 1.10)

1	2012	1.05 (0.90-	0.88 (0.76-	0.88 (0.75-	0.83 (0.67-
2					
3		1.21)	1.03)	1.04)	1.02)
4					
5					
6	2013	1.03 (0.89-	0.81 (0.69-	0.82 (0.69-	0.80 (0.65-
7					
8		1.20)	0.95)	0.96)	0.98)
9					
10					
11					
12	2014	1.09 (0.94-	0.82 (0.70-	0.83 (0.71-	0.72 (0.58-
13					
14		1.27)	0.96)	0.98)	0.90)
15					
16					
17					
18	2015	1.54 (1.31-	1.07 (0.91-	1.11 (0.94-	1.09 (0.87-
19					
20		1.80)	1.26)	1.32)	1.36)
21					
22					

All numbers indicate ORs and Confidence Intervals unless otherwise stated. *DAPT: dual antiplatelet therapy; Model 1: Without DAPT duration recommendation; Model 2: Final model; Model 3: Excluding patients with vascular events during follow up; Model 4: Excluding patients derived to another hospital

Table 3. Characteristics of study patients according to DAPT duration recommended at the PCI hospital discharge.

	No DAPT* or ≤1 month (n=1212)	DAPT 2- 11 months (n=581)	DAPT ≥12 months (n=6486)	Unspecified (n=2432)	P for trend (excluding unspecified)
Patient Characteristics					
Age, mean (SD)	62 (13.2)	61.2 (13.6)	61.3 (12.6)	61.6 (13.1)	0.221
Women	224 (18.5)	117 (20.1)	1333 (20.6)	539 (21.8)	0.107
Weight (1174 missing)	77.6 (13.7)	78.4 (13.8)	78.3 (13.6)	78.1 (14.4)	0.193
Cardiovascular risk factors					
Current smoker	601 (49.6)	303 (52.2)	2937 (45.3)	1142 (47)	0.001
Diabetes mellitus	243 (20.1)	93 (16)	1234 (19)	483 (19.9)	0.723

1		467	171	2589		
2	Hypercholesterolemia				912 (37.5)	0.039
3		(38.5)	(29.4)	(39.9)		
4						
5						
6			259	3075		
7	Hypertension	569 (47)			1107 (45.5)	0.550
8			(44.6)	(47.4)		
9						
10						
11						

History

15	Chronic Hepatic					
16	Disease	22 (1.8)	7 (1.2)	61 (0.9)	22 (0.9)	0.007
17						
18	Previous acute					
19	myocardial infarction	82 (6.8)	35 (6)	559 (8.6)	227 (9.3)	0.010
20						
21	Stroke or transient					
22	ischemic attack	44 (3.6)	18 (3.1)	166 (2.6)	65 (2.7)	0.031
23						
24	Previous					
25	percutaneous	59 (4.9)	28 (4.8)	455 (7)	182 (7.5)	0.002
26	revascularization					
27						
28	Previous surgical					
29	revascularization	6 (0.5)	3 (0.5)	78 (1.2)	25 (1)	0.014
30						
31	Chronic renal					
32	impairment	64 (5.3)	28 (4.8)	329 (5.1)	145 (6)	0.825
33						
34	Previous diagnosis of					
35	chronic heart failure	98 (8.1)	36 (6.2)	539 (8.3)	249 (10.2)	0.495
36						
37						
38						
39						
40						
41						
42						
43						
44						
45						
46						
47						
48						
49						
50						
51						
52						
53						
54						
55						
56						
57						
58						
59						
60						

1	Previous diagnosis of					
2						
3	peripheral arterial	58 (4.8)	28 (4.8)	230 (3.6)	132 (5.4)	0.020
4						
5	disease					
6						
7						
8						
9	Previous Antiplatelet	189	88	965		
10					411 (16.9)	0.518
11	treatment	(15.6)	(15.2)	(14.9)		
12						
13						
14						
15	Two or more	457	187	2618		
16					949 (39)	0.010
17	diseased vessels	(37.7)	(32.2)	(40.4)		
18						
19						
20	Vessel responsible					
21						
22						
23	Left anterior	378	234	2800		
24					973 (40)	<0.001
25	coronary artery	(31.2)	(40.3)	(43.2)		
26						
27						
28						
29	Right coronary	592	235	2475		
30					944 (38.8)	<0.001
31	artery	(48.8)	(40.5)	(38.1)		
32						
33						
34						
35	Circumflex coronary		71	869		
36		182 (15)	(12.2)	(13.4)	279 (11.5)	0.218
37	artery					
38						
39						
40						
41	Left main Coronary					
42		3 (0.3)	0	65 (1)	19 (0.8)	0.002
43	artery					
44						
45						
46						
47	No. of treated vessels					
48		1.02	1.05	1.05		
49	per patient, mean				1.05 (0.3)	<0.001
50		(0.1)	(0.2)	(0.3)		
51	(SD)					
52						
53						
54						
55		1171	561	6057		
56	Stent				2094 (86.1)	<0.001
57		(96.6)	(96.6)	(93.4)		
58						
59						
60						

1		1154	536	3437	1571		
2	Bare metal					<0.001	
3		(95.2)	(92.3)	(53)	(64.6)		
4							
5							
6		17	26	2756			
7	Drug-eluting				578 (23.8)	<0.001	
8		(1.4)	(4.5)	(42.5)			
9							
10							
11							
12	No. of stents per	1.15	1.22	1.19			
13							
14	patient, mean (SD)	(0.5)	(0.6)	(0.7)	1.08 (0.7)	0.665	
15							
16							
17							
18	Admission Features						
19							
20							
21	Admission days;						
22			6.6				
23	mean (SD); (662	7 (4.7)	(5.8)	6.8 (5.8)	8.5 (11.2)	<0.001	
24	missing values)						
25							
26							
27							
28							
29	Discharged home						
30		904	438	3720			
31	from the PCI				1095 (45)	<0.001	
32		(74.6)	(75.4)	(57.4)			
33	hospital						
34							
35							
36							
37							

*DAPT: dual antiplatelet therapy

Table 4. Determinants of 12-month prescription and interhospital variability measures.

	Determinants of 12- month recommendation of DAPT*	Determinants of 12- month recommendation of DAPT excluding patients derived to another hospital
	N=8279	N=5062
	N centers = 10	N centers = 10
Obs per center: average (min- max)	828 (240-1750)	506 (122-986)
Previous heart failure	0.81 (0.59-1.11)	0.88 (0.57-1.37)
Drug eluting stent	28.75 (12.44- 66.43)	36.52 (14.08- 94.76)
Two or more treated vessels	1.50 (0.95-2.35)	2.00 (1.10-3.64)
Discharged home	0.40 (0.34-0.48)	N/A
Year		
2010	1 (ref.)	1 (ref.)

1	2011	2.60 (1.07-6.31)	2.40 (0.81-7.09)
2			
3			
4	2012	4.35 (1.77-10.65)	4.75 (1.57-14.43)
5			
6			
7	2013	9.88 (3.95-24.73)	9.28 (2.93-29.36)
8			
9			
10	2014	11.00 (4.31-	12.67 (3.86-
11			
12		28.08)	41.62)
13			
14			
15			
16	2015	14.23 (5.70-	29.40 (8.96-
17			
18			
19		35.65)	96.45)
20			
21			

Random effects

25	Random intercept	4.46 (1.71-11.60)	6.05 (2.36-15.52)
26			
27			
28	Random slope (drug eluting	1.10 (0.32-3.84)	1.00 (0.25-4.05)
29	stent)		
30			
31			
32			
33			
34	Random slope (year)	0.69 (0.39-1.24)	0.99 (0.53-1.87)
35			
36			
37			
38	Intraclass correlation (95% CI)	57.5 (34.2-77.9)	64.8 (41.7-82.5)
39			
40			
41	Median OR (95% CrI†)	7.49 (1.21-348)	10.44 (1.12-2428)
42			
43			

All numbers indicate ORs and Confidence Intervals unless otherwise stated

*DAPT: dual antiplatelet therapy; †CrI: credibility interval

44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1





Figure 1

254x190mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2



Patients alive	0	1	2	3	4	5	6	7	8	9	10	11	12
2010	1151	1140	1144	1141	1139	1130	1137	1135	1133	1132	1131	1131	1130
2011	1499	1497	1495	1494	1492	1489	1484	1480	1472	1460	1466	1463	1450
2012	1702	1690	1695	1693	1690	1689	1686	1685	1685	1680	1679	1679	1670
2013	1750	1741	1734	1731	1720	1724	1717	1713	1712	1711	1700	1704	1700
2014	1773	1765	1760	1757	1755	1753	1749	1745	1740	1737	1735	1729	1726
2015	1704	1779	1771	1766	1759	1754	1752	1750	1745	1742	1741	1741	1737

Figure 2

254x190mm (96 x 96 DPI)

Figure 4




Figure 3

254x190mm (96 x 96 DPI)

Supplemental methods

Data validation processes in the AMI Code registry

1. Automatic data validation processes to identify and feed-back missing data and incongruities.

2. Periodic data validation process every 3-6 months:

Since year 2011 this process was automated. The system automatically detects missing information in key variables and the identification of AMI codes that were activated by the emergency services (before admission) and were not included in the registry. Feed back for data validation is sent every 3-6 months for amendment or justification to the person responsible for data entry at each AMI Code Hospital.

Since year 2015 the automated process can be managed directly at any time by the person responsible for data entry in each hospital.

3. Specific studies:

In 2012 data were evaluated for **exhaustiveness**: all AMI cases consecutively admitted in 43 hospitals in Catalonia (10 AMI Code hospitals and 32 no AMI Code hospitals) during a 3 months period were registered and compared with the episodes registered in the AMI Code registry.

Between 88-92% of STEACS episodes were included in the AMI Code registry.

In 2013 concordance of the information between the AMI Code registry and the information from clinical records was assessed. 330 cases were analyzed and concordance was good for all key variables and there were no differences between hospitals.

1 **Supplemental tables**

2
3
4 Table 1S. ICD9 codes used for the identification of conditions and diseases present at index admission and for the
5
6 identification of events during follow up.
7
8

9


Disease or condition	ICD9 diagnostic or procedure code
Heart failure	428.0, 428.1, 428.22, 428.23, 428.3, 428.32, 428.33, 428.41, 428.43
Renal disease	585*
Neoplasia	140-239
Anemia	280-285
Chronic obstructive pulmonary disease	491-492, 494*, 496*
Peripheral arterial disease	440.2, 440.3, 440.4
Atrial fibrillation	427.3*
Events during follow up	
Acute myocardial infarction	410*, except: 410.*2
Ischemic stroke	433*, 434*, except: 433.*0, 434.*0
Haemorrhagic stroke	430*, 431*, 432*
Intraocular bleeding	362.81, 363.6, 363.61, 363.62, 376.32, 377.42, 379.23
Digestive bleeding	530.21, 530.7, 530.82, 531.0, 531.2, 531.4, 531.6, 532.0, 532.2, 532.4, 532.6, 533.0, 533.2, 533.4, 534.4, 534.6, 535.01, 535.11, 535.21, 535.31, 535.41, 535.51, 535.61, 535.71, 537.83, 562.02, 562.03, 562.12, 562.13, 569.3, 569.85, 578.1, 578.9
Other bleeding	246.3, 459.0, 602.1, 784.8, 596.7, 599.7, 852*, 997.02, 998.1,
Endoscopic treatment	444.3, 454.2, 454.3
Transfusion	990.4

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2S. ATC codes used for the identification of drug treatment

Drug treatment	ATC code
ASA	B01AC06, N02BA01, B01AC30
Ticlopidine	B01AC05
Clopidogrel	B01AC04
Prasugrel	B01AC22
Ticagrelor	B01AC24
Dabigatran etexilate	B01AE07
Rivaroxaban	B01AF01
Apixaban	B01AF02
Beta-blocker	C07
ACE inhibitor	C09
Statins	C10AA

Supplemental figure. DAPT duration recommended in each hospital by year of episode



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page num
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title and abstract page 3 (Design subheading)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 3. Abstract
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 6
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 6 (last paragraph)
Methods			
Study design	4	Present key elements of study design early in the paper	Pages 8-9
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Pages 8-9
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	Pages 8-9
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Pages 8-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Pages 8-9
Bias	9	Describe any efforts to address potential sources of bias	Page 11 (sensitivity analyses)
Study size	10	Explain how the study size was arrived at	Page 9 (study population)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 9-11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	Pages 10-11 Pages 10-11 Pages 10-11 Pages 10-11 Page 11
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-	Page 12

		up, and analysed	
		(b) Give reasons for non-participation at each stage	Page 12
		(c) Consider use of a flow diagram	Fig 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Tables 1, 3
		(b) Indicate number of participants with missing data for each variable of interest	Tables 1, 3
		(c) Summarise follow-up time (eg, average and total amount)	Page 9
Outcome data	15*	Report numbers of outcome events or summary measures over time	Fig 2
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Tables 2, 4
		(b) Report category boundaries when continuous variables were categorized	Tables 2, 4
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Tables 2, 4
Discussion			
Key results	18	Summarise key results with reference to study objectives	Page 14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Pages 5 and 17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Pages 14-18
Generalisability	21	Discuss the generalisability (external validity) of the study results	Pages 14-18
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 5

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-Segment-Elevation Acute Coronary Syndrome. A population-based cohort study in Catalonia (Spain)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028114.R1
Article Type:	Research
Date Submitted by the Author:	28-Mar-2019
Complete List of Authors:	Ribera, Aida; University Hospital Vall d'Hebron, Cardiology Ferreira-Gonzalez, Ignacio; University Hospital Vall d'Hebron, Cardiology Marsal, Josep Ramon; University Hospital Vall d'Hebron, Cardiology Oristrell, Gerard; University Hospital Vall d'Hebron, Cardiology Faixedas, Maria Teresa; Servei Català de la Salut, Catalonia, Spain Rosas, Alba; 4. Departament de Salut, Generalitat de Catalunya Tizón-Marcos, Helena; 5. Cardiology Department, Hospital del Mar, and Heart Diseases Biomedical Research Group and IMIM (Hospital del Mar Medical Research Institute), and Faculty of Medicine, Universitat Autonoma de Barcelona Rojas, Sergio; 6. Cardiology Department, Hospital Universitari de Tarragona Joan XXIII, IISPV, and Universidad Rovira Virgili Labata, Carlos; Cardiology Department, Hospital German Tries i Pujol Cardenas, Merida; Cardiology Department, Hospital Josep Trueta Homs, Silvia; Cardiology Department, Hospital Mútua de Terrassa Tomas-Querol, Carlos; Cardiology Department, Hospital Arnau de Villanova Garcia-Picart, Joan; 11. Cardiology Department, Hospital de la Santa Creu i Sant Pau Gomez-Hospital, Joan; Cardiology Department, Hospital de Bellvitge Pijoan, Jose; BioCruces Health Research Institute Masotti, Monica; Cardiology Department, Hospital Clínic Mauri, Josepa; Departament de Salut, Generalitat de Catalunya Garcia Dorado, David; University Hospital Vall d'Hebron, Cardiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Health services research
Keywords:	dual antiplatelet therapy, ST-elevation myocardial infarction, persistence with treatment, percutaneous coronary intervention

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **Persistence with dual antiplatelet therapy after percutaneous coronary intervention**
4
5 **for ST-Segment-Elevation Acute Coronary Syndrome. A population-based cohort**
6
7 **study in Catalonia (Spain)**
8
9

10
11 Aida Ribera^{1,2}, PhD; Ignacio Ferreira-González^{1,2}, MD PhD; Josep Ramón Marsal^{1,2}, PhD;
12
13 Gerard Oristrell^{1,2}, MD Maria Teresa Faixedas³, MD; Alba Rosas⁴, PhD; Helena Tizón-
14
15 Marcos⁵, MD; Sergio Rojas⁶, MD; Carlos Labata⁷, MD; Mérida Cárdenas⁸, MD; Silvia
16
17 Homs⁹, MD; Carlos Tomás-Querol ¹⁰, MD; Joan Garcia-Picart¹¹, MD; Joan A. Gomez-
18
19 Hospital¹², MD, PhD; Jose Ignacio Pijoan^{2,13}, MD PhD; Monica Masotti¹⁴, MD; Josepa
20
21 Mauri ^{4,7}, MD PhD; David García-Dorado¹, MD PhD
22
23

24
25
26 On behalf of the VESA Study and Codi IAM Investigators
27

- 28 1. Cardiology Department, Vall d'Hebrón Hospital, Vall d'Hebron Research
29 Institute (VHIR) and Universitat Autònoma de Barcelona. Barcelona, Spain
30
- 31 2. CIBER de Epidemiología y Salud Pública (CIBERESP). Spain
32
- 33 3. Servei Català de la Salut, Catalonia, Spain
34
- 35 4. Departament de Salut, Generalitat de Catalunya, Catalonia, Spain.
36
- 37 5. Cardiology Department, Hospital del Mar, and Heart Diseases Biomedical
38 Research Group and IMIM (Hospital del Mar Medical Research Institute), and
39 Faculty of Medicine, Universitat Autònoma de Barcelona. Spain
40
- 41 6. Cardiology Department, Hospital Universitari de Tarragona Joan XXIII, IISPV,
42 and Universidad Rovira Virgili. Tarragona. Spain.
43
- 44 7. Cardiology Department, Hospital German Trias i Pujol. Barcelona. Spain.
45
- 46 8. Cardiology Department, Hospital Josep Trueta. Girona. Spain.
47
- 48 9. Cardiology Department, Hospital Mútua de Terrassa. Barcelona. Spain.
49
- 50 10. Cardiology Department, Hospital Arnau de Villanova. Lleida. Spain.
51
52
53
54
55
56
57
58
59
60

1
2
3 11. Cardiology Department, Hospital de la Santa Creu i Sant Pau. Barcelona. Spain.
4

5 12. Cardiology Department, Hospital de Bellvitge. Barcelona. Spain
6

7
8 13. Clinical Epidemiology Unit, Hospital Universitario Cruces/BioCruces Health
9
10 Research Insitute, Bilbao. Spain
11

12
13 14. Cardiology Department, Hospital Clínic, Barcelona. Spain.
14
15
16
17

18
19 **Corresponding author**

20
21
22 Ignacio Ferreira-González. Cardiovascular Epidemiology Unit. Cardiology Department.
23

24 University Hospital Vall d'Hebron. Psg. Vall d'Hebron, 119-129 08035 Barcelona. Spain
25

26
27 nachoferreira@secardiologia.es
28

29 tel. 932746177
30
31
32
33

34 **Word count:** 4037
35

36 **Keywords:** dual antiplatelet therapy, persistence with treatment, ST-elevation
37
38 myocardial infarction, percutaneous coronary intervention
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Guidelines recommending 12 months dual antiplatelet therapy (DAPT) in patients with ST-elevation acute coronary syndrome (STEACS) undergoing percutaneous coronary intervention (PCI) were published in year 2012. We aimed to describe the influence of guidelines implementation on the trend in 12-month persistence with DAPT between 2010 and 2015 and to evaluate its relationship with DAPT duration regimens recommended at discharge from PCI hospitals.

Design: Observational study based on region-wide registry data linked to pharmacy billing data for DAPT follow up.

Setting. All PCI hospitals (10) belonging to the AMI-Code network in Catalonia (Spain)

Participants: 10,711 STEACS patients undergoing PCI between 2010 and 2015 were followed up.

Primary and secondary outcome measures: Primary outcome was 12 month persistence with DAPT. Calendar year quarter, publication of guidelines; DAPT duration regimen recommended in the hospital discharge report, baseline patient characteristics and significant interactions were included in mixed effects logistic regression based interrupted time-series models. **Results:** The proportion of patients on-DAPT at 12 months increased from 58% (56-60) in 2010 to 73% (71-75) in 2015. The rate of 12-months persistence with DAPT significantly increased after the publication of clinical guidelines with a time lag of one year (OR=1.20; 95% CI: 1.11-1.30). A higher risk profile, more extensive and complex coronary disease, use of drug-eluting stents (OR=2.02; 95% CI: 1.61-2.53) and a 12-months DAPT regimen recommendation at discharge from the PCI hospital (OR=5.92; 95% CI: 3.34-10.52) were associated with 12-months persistence. **Conclusion:** Persistence with 12-month DAPT has increased

1
2
3 since publication of clinical guidelines. Even though most patients were discharged on
4
5 DAPT, only 73% with potential indication were on-DAPT 12 months after PCI. A
6
7
8 guideline-based recommendation at PCI hospital discharge was highly associated with
9
10 full persistence with DAPT. Establishing evidence-based, common prescribing criteria
11
12
13 across hospitals in the AMI-network would favour adherence and reduce variability.
14
15
16
17

18 **Strengths and limitations of this study**

- 19
20
21 • The study describes the trends in persistence with DAPT during 2010-2015 in a
22
23 region-wide unselected comprehensive cohort of patients using administrative
24
25 data linked to a clinical registry
- 26
27
28 • It also evaluates the impact of the DAPT duration recommended at the PCI
29
30 hospital discharge on 12-months persistence
- 31
32
33 • Limitations of using observational registry data include the possibility of coding
34
35 errors and the inability to accurately identify specific contraindications for
36
37 treatment or other patient characteristics that might be relevant for the study
38
39 aims
- 40
41
42
43 • The use of pharmacy refill data as a proxy of patients adherence and
44
45 persistence has also limitations which have been extensively described
46
47
48
49
50

51 **Study funding**

52
53
54 The study was supported by Instituto de Salud Carlos III grand number PI13/00399 and
55
56 the Fundació la Marató de TV3 grand number 430/U/2015. The funders did not have
57
58 any role in the study design and development.
59
60

Competing interest statement

All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work

For peer review only

Introduction

The need of dual antiplatelet therapy (DAPT) combining aspirin and an ADP-receptor blocker for at least 12 months in patients with ST-elevation acute coronary syndrome (STEACS) undergoing percutaneous coronary intervention (PCI) is well established and was incorporated into clinical guidelines in 2012[1,2].

Adherence of patients to this strategy is crucial to ensure its efficacy. Adherence to medication is usually defined[3] as the extent to which patients take medications as prescribed by their health care providers and persistence is defined as time from initiation to discontinuation of a therapy. Patients' persistence with DAPT may be influenced by several factors but will depend strongly on whether they ultimately receive a correct prescription from their physicians in the primary care setting. Patients may receive recommendations from various health providers at different stages of their process of care, from the interventionist cardiologist to their primary physician. It could be hypothesized that the last would tend to relay on the recommendation of the more specialized health professional. Thus, one potential determinant of patient's persistence with DAPT for at least 12 months is the instructions provided in the discharge report of the hospital where the patient was attended during the acute phase.

In Catalonia, an autonomous region of Spain, the acute care of STEACS is organized through a region-wide network, the Acute Myocardial Infarction (AMI) Code, to derive patients with suspected STEACS to one of the 10 reference hospitals with PCI capability. Performance of the AMI Code is prospectively and exhaustively registered[4,5], providing an appropriate tool for quality evaluation. The Catalan

1
2
3 Health Information System systematically registers, among other, data on pharmacy
4 refills. Pharmacy billing data, although indirect, is an accepted method for evaluating
5 persistence with treatment in large patient cohorts[3,6].
6
7
8
9

10 The aims of the present study were: first, to describe persistence with DAPT for at least
11 12 months in patients with STEACS undergoing PCI from 2010 to 2015; second, to
12 evaluate the influence of publication of guidelines incorporatins this specific
13 recommendation on increasing the rate of 12-monhts persistence along time; and
14 third, to evaluate the association of the DApT duration recommended at the PCI
15 hospital discharge with patients' persistence with treatment for at least 12 months.
16
17
18
19
20
21
22
23
24
25
26

27 **Methods**

28 *Data sources*

29
30
31 Data were obtained through the Public Data Analysis for Health Research and
32 Innovation Program (PADRIS). The PADRIS allows access to information from different
33 sources on public healthcare resources usage for the population of Catalonia linked at
34 the patient level with warranted accomplishment of ethical principles. Specifically, for
35 the present study we linked data of the pharmacy billing registry with the AMI Code
36 Registry. The AMI Code registry was launched in 2010 to evaluate performance of the
37 AMI Code [4,5]. Exhaustiveness and quality of data is assessed periodically (see
38 supplemental methods for details). The database belongs to the Catalan Department
39 of Health and includes demographic, clinical, and therapeutic data for each episode of
40 hospitalization for STEACS. It conforms to the ethical and legal requirements for
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 research purposes. The study obtained ethics approval from the Vall d'Hebron Clinical
4
5 Research Ethics Committee.
6

7
8 The registry was completed for the purpose of the present analysis with retrospective
9
10 collection of additional specific data: diseased vessels, responsible vessel, stent type,
11
12 number of stents. The recommendation of antithrombotic drugs was also collected *ad*
13
14 *hoc* for the study from the discharge report. The recommendation of DAPT was
15
16 defined as the recommendation of Acetylsalicylic acid (ASA) and clopidogrel, prasugrel
17
18 or ticagrelor for specified periods. If the recommended duration of DAPT was not
19
20 specified, the discharge recommendation pattern was classified as "unspecified". A
21
22 local investigator at each center performed the specific retrospective data collection.
23
24
25

26
27 History of major haemorrhage, neoplasia, renal disease, heart failure, peripheral
28
29 arterial disease and atrial fibrillation, were obtained from minimum basic data set
30
31 (MBDS) diagnoses coded in hospitalization episodes occurring in the previous three
32
33 months before index hospitalization. Major haemorrhage was defined as: a diagnosis
34
35 of digestive bleeding in any diagnostic position (primary or secondary) together with a
36
37 procedure code for endoscopic treatment or for transfusion of blood products, or a
38
39 diagnosis of haemorrhagic stroke, or a diagnosis of intraocular haemorrhage, or a
40
41 diagnosis of other types of haemorrhage together with a procedure code for
42
43 transfusion of blood products. Major ischemic events (AMI or stroke) and major
44
45 haemorrhage during the 12 months following the index episode were obtained in the
46
47 same way. Mortality during the 12 months following the index episode was obtained
48
49 from the insured registry status.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Drug treatment during the 12-month post-discharge follow up was obtained from the
4
5 pharmacy billing registry. ICD9 and ATC codes used for the identification of study
6
7 variables are listed in the supplemental tables 1 and 2.
8
9

10 11 12 13 14 ***Study population***

15
16 We included all consecutive patients who survived a STEACS between January 2010
17
18 and December 2015, received primary or post fibrinolysis PCI in one of the 10
19
20 reference hospitals of the AMI Code network, were discharged home or transferred to
21
22 another hospital and survived at least one month after AMI. New episodes of STACS
23
24 occurring to the same patients during the study period were only accounted as follow
25
26 up events. Patients with likely contraindication for DAPT (history of major bleeding or
27
28 neoplasm in the three months prior to the index episode and patients requiring
29
30 anticoagulation) were excluded.
31
32
33
34
35
36
37
38

39 ***Persistence with treatment***

40
41 DAPT was defined as the concomitant use of ASA and a P2Y₁₂ antagonist. Persistence
42
43 with DAPT was estimated by identification of consecutive months with pharmacy refills
44
45 with one container of each agent in the 12-month period after hospital discharge.
46
47 Because pharmacy billing is registered in a monthly basis and the exact day of
48
49 dispensation is unknown, we considered that a monthly dispensation until at least
50
51 month 11 after the index episode would approximate a 12-months treatment period. If
52
53 more than one container were dispensed in one month, the excess containers were
54
55 pulled along the following months. Non-persistence was defined as either
56
57
58
59
60

1
2
3 discontinuation or a break in therapy of at least two months after pulling along the
4
5 excess containers. To describe persistence over the whole study period we estimated
6
7 the proportion of patients alive and within the 12 months after discharge window who
8
9 were on treatment on each month[7].
10
11
12

13
14 The primary outcome was a patients' persistence with DAPT for 12 months following
15
16 discharge (or in other words, patients withdrawing both agents from the pharmacy
17
18 until at least month 11).
19
20
21

22 23 **Statistical analysis**

24
25 We compared baseline characteristics between patients persisting with DAPT for at
26
27 least 12 months and patients withdrawing DAPT before 12 months with chi square test
28
29 or t test when appropriate. We tested for trends in patient's characteristics along
30
31 calendar year of discharge for the index procedure with Jonckheere-Terpstra test for
32
33 differences between ordered categories.
34
35
36

37
38 To evaluate the influence of time, guidelines publication and the DAPT duration
39
40 recommended in the PCI hospital discharge report we modelled logistic regression
41
42 based interrupted time-series analysis[8], adjusting for baseline characteristics. As a
43
44 first step, because it is expected that guidelines publication influences practice with a
45
46 time delay, we plotted the proportion of patients persisting on-DAPT for 12 months by
47
48 year quarter of discharge from the PCI hospital and we tested models with a slope
49
50 change (indicating the start of guidelines implementation) at different lag periods after
51
52 publication of the European clinical guidelines (last quarter of 2012). Once the lag
53
54 period between guidelines publication and implementation of recommendations was
55
56 estimated we included patient characteristics and second or third level interactions of
57
58
59
60

1
2
3 each characteristic with year quarter and moment of implementation. We coded time
4
5 (T) as the time elapsed since the publication of guidelines plus the lag period (in
6
7 quarters) and a dummy variable (X_t) indicating the pre-implementation period (coded
8
9 0) or the post-implementation period (coded 1)[9].
10
11
12
13
14

15 The standard model specification was the following:
16

$$17 \quad \text{logit}(Y_t) = \beta_0 + \beta_1 T + \beta_2 X_t + \beta_3 TX_t$$

18
19 Where β_0 represents the baseline level at $T = 0$, β_1 is interpreted as the change in
20
21 outcome associated with a time unit (quarter) increase (representing the underlying
22
23 pre-implementation trend), β_2 is the level change following the implementation and
24
25 β_3 indicates the slope change following the implementation (using the interaction
26
27 between time and implementation: TX_t). Additional terms can be added to model the
28
29 effect of other covariables and their interactions with T and X_t and to include random
30
31 effects. Note that we set $T = 0$ at the quarter where we observed a significant change
32
33 in the slope at a lag time after guidelines publication.
34
35
36
37
38
39
40
41
42

43 We took into account the clustered structure of data with patients being treated and,
44
45 most importantly, with recommendations on DAPT duration being provided in
46
47 different hospitals, by introducing random effects in the logistic regression models.
48

49 . We tested whether models including random intercept for hospital and random
50
51 slopes for each independent variable were significant using a deviance –based test of
52
53 hypothesis.
54
55

56 Variable selection for multilevel modelling was based on the bivariate associations
57
58 with the rate of each dependent variable. Candidate individual variables were those
59
60

1
2
3 described in tables 1 and 2. Type of antiplatelet drug was not included in the
4
5 multivariable analysis because it was highly correlated with the year of episode, as new
6
7 antiplatelet agents (ticagrelor and prasugrel) were introduced later during the study
8
9 period. We retained in the final model all variables with a p value<0.2.
10
11

12
13 Plots of predicted probability values were used to show marginal effects of variables of
14
15 interest and variability between centres.
16
17

18 19 20 ***Sensitivity analyses***

21
22 Because a substantial proportion of patients were returned to their reference hospital
23
24 and because it was unknown whether the DAPT duration recommendation was
25
26 changed at discharge from the second hospital, we performed sensitivity analyses
27
28 excluding these patients. Additionally, because ischemic and haemorrhagic events
29
30 occurring during follow up would change the treatment length, sensitivity analyses
31
32 were also performed by excluding patients suffering any vascular event during follow
33
34 up.
35
36
37
38
39
40
41

42 ***Patient and Public Involvement***

43
44 The present study did not involve individual patients or public agencies.
45
46
47
48

49 **Results**

50
51 After excluding patients with likely contraindication for DAPT (figure 1), we identified
52
53 10,711 STEACS patients undergoing PCI who were potential candidates to receive
54
55 DAPT for at least 12 months and survived for at least one month after discharge. 631
56
57 (5.9%) patients experienced an ischemic major event (AMI or stroke) within 12 months
58
59
60

1
2
3 after the index episode, 100 (0.9%) had a major haemorrhage and 280 (2.6%) died
4
5 between one and 12 months after the index episode. After excluding patients who
6
7 died or were lost to follow up and patients with errors in quarter allocations, 10,262
8
9 patients remained for analysis.
10
11

12
13 Table 1 shows characteristics of study patients depending on persistence with DAPT.
14
15 Patients persisting for at least 12 months had higher prevalence of cardiovascular risk
16
17 factors (hypertension, diabetes and hypercholesterolemia), higher rate of a previous
18
19 history of cardiovascular disease, more extended coronary disease, higher rate of drug
20
21 eluting stents implantation and slightly higher ischemic risk (as measured with the
22
23 DAPT score[10]). Persisting patients were more often transferred to their reference
24
25 hospital and had had a prescription for a longer DAPT period at discharge from the PCI
26
27 hospital and had had a prescription for a longer DAPT period at discharge from the PCI
28
29 hospital.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Characteristics of study patients according to DAPT persistence during follow up.

	DAPT <12 months (n=3684)		DAPT ≥ 12 months (n=6578)		Total (n=10262)		P value
	N	n (%)	N	n (%)	N	n (%)	
Age	3684	61.19 ± 13.21	6578	61.18 ± 12.38	10262	61.19 ± 12.69	0.578
Gender (Female)	3684	765 (20.8%)	6578	1319 (20.1%)	10262	2084 (20.3%)	0.399
Smoke (Y)	3684	1774 (48.2%)	6578	3042 (46.2%)	10262	4816 (46.9%)	0.064
Hypertension (Y)	3684	1622 (44%)	6578	3142 (47.8%)	10262	4764 (46.4%)	<0.001
Diabetes (Y)	3684	647 (17.6%)	6578	1298 (19.7%)	10262	1945 (19%)	0.008
Hypercholesterolaemia (Y)	3684	1291 (35%)	6578	2678 (40.7%)	10262	3969 (38.7%)	<0.001
Polyvascular disease (Y)*	3684	530 (14.4%)	6578	1048 (15.9%)	10262	1578 (15.4%)	0.038
Previous stroke or transient ischaemic attack (Y)	3684	101 (2.7%)	6578	172 (2.6%)	10262	273 (2.7%)	0.704
Previous acute myocardial infarction (Y)	3684	265 (7.2%)	6578	570 (8.7%)	10262	835 (8.1%)	0.010
Previous percutaneous coronary intervention (Y)	3684	194 (5.3%)	6578	482 (7.3%)	10262	676 (6.6%)	<0.001
Previous by-pass surgery (Y)	3684	20 (0.5%)	6578	85 (1.3%)	10262	105 (1%)	<0.001
History of peripheral arteriopathy (Y)	3684	153 (4.2%)	6578	276 (4.2%)	10262	429 (4.2%)	0.957
Comorbidity (Y)†	3684	462 (12.5%)	6578	885 (13.5%)	10262	1347 (13.1%)	0.191
Hepatopathy (Y)	3684	48 (1.3%)	6578	56 (0.9%)	10262	104 (1%)	0.030
History of Renal Impairment (Y)	3684	185 (5%)	6578	320 (4.9%)	10262	505 (4.9%)	0.741
History of Heart Failure (Y)	3684	272 (7.4%)	6578	583 (8.9%)	10262	855 (8.3%)	0.009
Affected number of vessels ≥2 (Y)	3684	1275 (34.6%)	6578	2731 (41.5%)	10262	4006 (39%)	<0.001
Number of treated vessels	3613	1.03 ± 0.21	6516	1.06 ± 0.26	10129	1.05 ± 0.25	<0.001
Drug eluting stent (Y)	3684	572 (15.5%)	6578	2704 (41.1%)	10262	3276 (31.9%)	<0.001
DAPT Score Points	3684	1.20 ± 1.20	6578	1.28 ± 1.17	10262	1.25 ± 1.18	<0.001
Discharged home (Y)	3684	2233 (60.6%)	6578	3672 (55.8%)	10262	5905 (57.5%)	<0.001
DAPT recommendation at discharge	3684		6578		10262		<0.001
1 month		875 (23.8%)		295 (4.5%)		1170 (11.4%)	
<12 months		385 (10.5%)		173 (2.6%)		558 (5.4%)	
≥12months		1522 (41.3%)		4732 (71.9%)		6254 (60.9%)	
unknown		902 (24.5%)		1378 (20.9%)		2280 (22.2%)	

*Polyvascular disease was defined as presence of at least two of the following conditions: previous myocardial infarction or percutaneous coronary or surgical revascularization; history of peripheral arteriopathy; history of stroke or transient ischaemic attack. †Comorbidity was defined as presence of one of the following conditions: hepatopathy, history of renal impairment, history of heart failure

1
2
3 The rate of patients on-DAPT after discharge from the PCI hospital was 91% (95% CI:
4 90-91) without relevant differences between years (supplemental figure 1). The
5
6 proportion of patients on-DAPT at 12 months significantly increased from 58% (56-61)
7
8 in 2010 to 73% (71-75) in 2015. The larger increase in 12-month persistence was
9
10 observed between 2014 (64% [62-66]) and 2015, two years after the publication of
11
12 clinical guidelines.
13
14
15
16

17 Some baseline characteristics showed a temporal trend over the study period 2010-
18
19 2015 (table 2). The prevalence of cardiovascular risk factors (smoking, hypertension
20
21 and hypercholesterolemia) and comorbidities increased slightly. Likewise, the number
22
23 of treated vessels, the rate of drug eluting stents implantation also increased with
24
25 time.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Characteristics of study patients by year of discharge for the index admission.

	2010 (n=1537)	2011 (n=1628)	2012 (n=1760)	2013 (n=1779)	2014 (n=1779)	2015 (n=1779)	P value
Age	61 ± 12.92	61.01 ± 13.09	60.97 ± 12.52	61.27 ± 12.4	61.24 ± 12.72	61.58 ± 12.53	0.325
Gender	310 (20.2%)	311 (19.1%)	372 (21.1%)	359 (20.2%)	352 (19.8%)	380 (21.4%)	0.389
Smoke	686 (44.6%)	754 (46.3%)	811 (46.1%)	839 (47.2%)	840 (47.2%)	886 (49.8%)	0.004
Hypertension	674 (43.9%)	729 (44.8%)	808 (45.9%)	838 (47.1%)	844 (47.4%)	871 (49%)	0.001
Diabetes	296 (19.3%)	319 (19.6%)	340 (19.3%)	327 (18.4%)	325 (18.3%)	338 (19%)	0.438
Hypercholesterolaemia	541 (35.2%)	621 (38.1%)	648 (36.8%)	710 (39.9%)	742 (41.7%)	707 (39.7%)	<0.001
Polyvascular disease*	232 (15.1%)	253 (15.5%)	301 (17.1%)	259 (14.6%)	278 (15.6%)	255 (14.3%)	0.370
Previous stroke or transient ischaemic attack	42 (2.7%)	32 (2%)	45 (2.6%)	40 (2.2%)	65 (3.7%)	49 (2.8%)	0.126
Previous acute myocardial infarction	127 (8.3%)	142 (8.7%)	163 (9.3%)	151 (8.5%)	127 (7.1%)	125 (7%)	0.029
Previous percutaneous coronary intervention	94 (6.1%)	104 (6.4%)	123 (7%)	116 (6.5%)	118 (6.6%)	121 (6.8%)	0.485
Previous by-pass surgery	10 (0.7%)	16 (1%)	17 (1%)	19 (1.1%)	18 (1%)	25 (1.4%)	0.056
History of peripheral arteriopathy	51 (3.3%)	70 (4.3%)	93 (5.3%)	66 (3.7%)	86 (4.8%)	63 (3.5%)	0.876
Comorbidity†	155 (10.1%)	190 (11.7%)	233 (13.2%)	243 (13.7%)	266 (15%)	260 (14.6%)	<0.001
Hepatopathy	16 (1%)	12 (0.7%)	24 (1.4%)	24 (1.3%)	13 (0.7%)	15 (0.8%)	0.578
History of Renal Impairment	70 (4.6%)	75 (4.6%)	71 (4%)	86 (4.8%)	89 (5%)	114 (6.4%)	0.009
History of Heart Failure	80 (5.2%)	118 (7.2%)	154 (8.8%)	159 (8.9%)	187 (10.5%)	157 (8.8%)	<0.001
Affected number of vessels ≥2	594 (38.6%)	617 (37.9%)	679 (38.6%)	707 (39.7%)	688 (38.7%)	721 (40.5%)	0.188
Number of treated vessels	1.04 ± 0.25	1.03 ± 0.23	1.05 ± 0.26	1.05 ± 0.24	1.05 ± 0.26	1.06 ± 0.24	0.003
Drug eluting stent	462 (30.1%)	388 (23.8%)	472 (26.8%)	493 (27.7%)	652 (36.6%)	809 (45.5%)	<0.001
DAPT Score Points	1.24 ± 1.2	1.24 ± 1.19	1.26 ± 1.17	1.26 ± 1.17	1.22 ± 1.16	1.28 ± 1.19	0.435
Discharged home	961 (62.5%)	951 (58.4%)	933 (53%)	1042 (58.6%)	959 (53.9%)	1059 (59.5%)	0.041
DAPT recommendation at discharge							<0.001
1 month	281 (18.3%)	259 (15.9%)	243 (13.8%)	181 (10.2%)	135 (7.6%)	71 (4%)	
<12 months	150 (9.8%)	137 (8.4%)	100 (5.7%)	69 (3.9%)	65 (3.7%)	37 (2.1%)	
≥12 months	792 (51.5%)	871 (53.5%)	975 (55.4%)	1086 (61%)	1154 (64.9%)	1376 (77.3%)	

	2010 (n=1537)	2011 (n=1628)	2012 (n=1760)	2013 (n=1779)	2014 (n=1779)	2015 (n=1779)	P value
unknown	314 (20.4%)	361 (22.2%)	442 (25.1%)	443 (24.9%)	425 (23.9%)	295 (16.6%)	

*Polyvascular disease was defined as presence of at least two of the following conditions: previous myocardial infarction or percutaneous coronary or surgical revascularization; history of peripheral arteriopathy; history of stroke or transient ischaemic attack. †Comorbidity was defined as presence of one of the following conditions: hepatopathy, history of renal impairment, history of heart failure

For peer review only

1
2
3 The overall rate of explicit DAPT recommendation for at least 12 months in the
4 hospital discharge reports was 51% (49-53) in 2010 and increased to 77% (75-79) in
5
6
7
8 2015 but it was highly variable between hospitals (supplemental figure 2).

9
10 Figure 2 shows the observed proportion of patients persisting with DAPT for at least 12
11
12
13 month at each time point and the interrupted time series model fitted after setting a
14
15 one year lag period from publication to implementation of guidelines.

16
17 In interrupted time series logistic regression (Table 3), variables showing association
18
19
20 with 12 months persistence on DAPT were two or more diseased vessels, higher
21
22
23 number of stents implanted, receiving drug eluting stents, hypercholesterolemia, a
24
25
26 previous surgical procedure and a recommendation of DAPT for a longer period at
27
28
29 discharge from the PCI hospital. Guidelines implementation had a positive effect on
30
31
32 persistence: a 20% increase in the odds of 12 months persistence each quarter after a
33
34
35 lag of one year since publication. The effect of drug eluting stents was attenuated with
36
37
38 time (OR for interaction: 0.97; 95%CI: 0.95-0.98) while the effect of prescription was
39
40
41 attenuated with time after guidelines implementation (OR for the interaction 0.87,
42
43
44 95%CI: 0.80-0.94 for a recommendation of ≥ 12 months and 0.89, 95%CI: 0.82-0.98 for
45
46
47 an unknown recommendation). The effect of implantation of drug eluting stents and
48
49
50 type of recommendation also varied between hospitals (significant random slopes).

Table 3. Factors associated with a persistence of at least 12 months as assessed with interrupted time series logistic regression model

Fixed effects	OR	95% CI	P value
Drug eluting stent	2.02	1.61 - 2.53	<0.001
Number of stents	1.21	1.12 - 1.31	<0.001
Recommendation at PCI hospital discharge (Ref. 1 month)	1.00		
<12 months	1.67	0.88 - 3.17	0.120
≥12 months	5.92	3.34 - 10.52	<0.001
unknown	2.23	0.82 - 6.02	0.115
Hypercholesterolemia	1.19	1.08 - 1.31	<0.001
Previous by-pass surgery	1.81	1.06 - 3.07	0.029
Two or more treated vessels	1.20	1.09 - 1.32	<0.001
Drug eluting stent * Time (quarter)	0.97	0.95 - 0.98	<0.001
Guidelines implementation	1.20	1.11 - 1.3	<0.001
Recommendation at PCI hospital discharge (Ref. 1 month) * Time (quarter)*Guidelines implementation			
<12 months	0.91	0.8 - 1.05	0.191
≥ 10 months	0.87	0.8 - 0.94	0.001
unknown	0.89	0.82 - 0.98	0.013
Random effects	Variance	95% CI	
Random - Intercept	0.46	0.11 – 5.16	
Random - Slopes			
Recommendation at PCI hospital discharge (Ref. 1 month)			
<12 months	0.38	0.15 – 4.21	
≥12 months	0.39	0.15 – 4.29	
unknown	2.00	0.45 – 22.19	
Drug eluting stent	0.09	0.02 – 1.00	
Adjusted ICC	0.087		

Results of sensitivity analyses, excluding patients with ischemic or haemorrhagic events during follow up, or excluding patients that were transferred to another centre after PCI were similar to the main analysis (Supplemental table 3).

The interaction between drug eluting stents and time can be seen in figure 3A. Because 12-months persistence increased with time in patients without drug eluting stents, the effect of type of stent is attenuated with time. The interaction of the recommendation pattern with time and guidelines implementation can be seen in figure 3B: 12-months persistence increased with time mainly in the subgroups with

1
2
3 shorter time specification in the discharge report and also in patients without a specific
4
5 recommendation, but this increase started after guidelines implementation (one year
6
7 after publication). Figure 3C shows a substantial reduction in the variability between
8
9 centres mainly due to an increase in the proportion of 12-months persistence in
10
11 patients attended in centres where the initial proportion was lower (significant
12
13 random intercept and slopes).
14
15
16
17
18
19

20 Discussion

21
22 According to published guidelines, all STEACS patients undergoing PCI without
23
24 contraindication should be kept on DAPT for at least 12 months unless an event occurs
25
26 that precludes continuing with this treatment. In this observational region-wide study
27
28 we have found an increase in the proportion of patients on-DAPT at 12 months from
29
30 58 to 73% in the period from 2010 to 2015, with an accelerated rate starting in the
31
32 fourth quarter of 2013, one year after the publication of European guidelines.
33
34
35

36
37 We also found a high variability between hospitals in the adherence to guidelines
38
39 when recommending DAPT for at least 12 months which leads to substantial
40
41 differences between hospitals in the rate of patients persisting with the recommended
42
43 DAPT. The progressive increase in the overall rate of 12-months persistence was
44
45 accompanied by a substantial reduction of interhospital variability.
46
47
48

49
50 Likelihood of patients persisting with DAPT for one year is strongly related to the
51
52 instructions given at the PCI hospital discharge, as we observed a lower rate of 12-
53
54 month persistence in patients receiving a discharge DAPT recommendation for less
55
56 than 12 months. Although a causal direct relationship between the established
57
58 recommendation in the more specialised setting and the final prescription at the
59
60

1
2
3 primary care setting cannot be stated on the basis of observational data, this finding
4
5 suggests that prescribing physicians strongly rely on the first recommendation
6
7 specified at the discharge report in the PCI hospital. Therefore, hospital cardiologists
8
9 should be kept aware of their impact and encouraged to be clear and specific enough
10
11 when providing DAPT time recommendations in the discharge report form.
12
13

14
15 The recommendation in clinical guidelines of DAPT for at least 12 months following
16
17 STEACS[1,2] was based on the duration of follow up of randomised clinical trials
18
19 designed for other purposes and[11–13], although a 12-month treatment seemed
20
21 reasonable [14], no randomized studies had been performed within the study period
22
23 aimed specifically at comparing 12 months DAPT with shorter periods in STEACS
24
25 patients receiving PCI and thus this recommendation might well be seen as somehow
26
27 arbitrary by some prescribers.
28
29
30

31
32 In 2015 the need for long term DAPT was reinforced by the recommendation of
33
34 extended DAPT beyond 12 months in patients with ACS receiving drug eluting
35
36 stents[15–17], but still safety concerns might induce some prescribers to be reluctant
37
38 to prolong DAPT, especially in patients with higher complexity[18]. Safety concerns
39
40 might also explain the high proportion of discharge reports with non-specified DAPT
41
42 period, which deserved special attention in our analyses. Cardiologists might be
43
44 reluctant to prescribe a specific duration of DAPT maybe fearing about the emergency
45
46 of events that increase the haemorrhagic risk at some point after discharge, thus
47
48 relaying on the follow up that will be made at the ambulatory setting. Our results
49
50 showing a high degree of persistence for patients without a specification of DAPT time
51
52 point out to the fact that this decision is not necessarily “incorrect”, and that health
53
54 providers coming later in the process of care are probably doing their job.
55
56
57
58
59
60

1
2
3 We might wonder whether the observed high variability between hospitals in the
4 instructions provided about DAPT duration actually reflects suboptimal quality of care
5 or confusion in the interpretation of international guidelines. In fact, although 2012
6 ESC guidelines state that DAPT must be continued for 12 months after STEACS with a
7 class of recommendation I, the level of evidence was established as C[1]. Thus, there
8 was general agreement that a minimum of 12 months of DAPT is likely to be beneficial
9 but based only on a consensus of experts or observational studies. Moreover, it is
10 literally stated that the given recommendation on DAPT duration should be “with a
11 strict minimum of 1 month for patients receiving BMS and 6 months for patients
12 receiving DES”, with Class IC and IIb respectively. These messages, which ultimately
13 reflected the lack of clinical trials aimed to answer the specific question about DAPT
14 duration, could have induced a perception of arbitrariness leading to variability in
15 clinical practice.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 In fact, the optimal duration of DAPT has not yet been totally established in more
35 contemporary clinical trials. The most recent randomized clinical trial conducted in
36 patients with STEACS aimed to assess the question of 12-month vs a 6-month DAPT
37 duration, showed that 6-month DAPT duration after primary PCI was non-inferior to
38 12-month duration to prevent major cardiovascular events[19]. In another trial in the
39 context of ACS, 12 months or longer DAPT duration versus 6 months was not
40 associated with lower major cardiovascular events and total mortality[20].
41
42
43
44
45
46
47
48
49
50

51 Regardless the level of the evidence, one would expect that a Class I recommendation
52 should be uniformly followed by clinicians. Moreover, as patient characteristics did not
53 substantially differed across hospitals, we should expect a lower variability between
54 hospitals. A large variation in individual country practices concerning the pattern of
55
56
57
58
59
60

1
2
3 DAPT duration after ACS has been described, suggesting that local systems are strong
4
5 drivers of DAPT duration[21]. These findings may imply that there is still room for
6
7 improvement in the quality of care of STEACS patients and that quality improvement
8
9 programs, whose efficacy and cost-effectiveness are still under evaluation, could be
10
11 useful to reduce variability in clinical practice[22]. This is of prime importance in the
12
13 context of the prescription of DAPT duration after ACS in which the clinician-driven
14
15 variability in prescription patterns adds to the different levels patients' adherence[21].
16
17 Higher atherosclerotic burden and increased ischemic risk was associated to better
18
19 persistence with DAPT. The need for 12-month DAPT schedules in patients treated
20
21 with drug eluting stents is clearly perceived by physicians but the magnitude of this
22
23 association varies largely between hospitals. This means that, even in clear indications,
24
25 there are different levels of adoption of emerging clinical recommendations in
26
27 hospitals belonging to the same AMI network.

28
29 It is also apparent from our data that the speed of adoption of clinical guidelines is
30
31 different among hospitals and that an acceptable and generalised level of adherence is
32
33 only reached after two years of implementation. Similar trends have been found in
34
35 other contexts and earlier periods[23–28] reporting DAPT use between 60-80% at
36
37 discharge and between 25-75 % at one year. In this sense, together with other quality
38
39 improvement initiatives, the use of population-based registries to provide audit and
40
41 feedback could be useful to promote quicker and smoother adoption of clinical
42
43 practice guidelines[29].
44
45
46
47
48
49
50
51
52
53
54

55
56 There are a number of assumptions that might be questionable: A number of factors
57
58 have been described to contribute to underprescription[30]. The complete process of
59
60

1
2
3 care and the definite prescription at the ambulatory setting is poorly known for
4
5 individual patients and has not been considered in this study. Changes in treatment
6
7 prescription might be justified by the patients' varying conditions during follow up. We
8
9 assume that hospital recommendation influences final prescription, and consequently,
10
11 final adherence to guidelines, but it can also be that both "prescribers" facing the same
12
13 patient share the same criteria for prescription. I.e. the hospital cardiologist might
14
15 have decided to recommend DAPT for a shorter period to an elderly patient with other
16
17 comorbidities and suboptimal quality of life due to mild digestive symptoms, even if
18
19 her objective bleeding risk is not high; similarly, the primary physician or the
20
21 cardiologist at the primary care setting might have also decided to be less aggressive
22
23 for the same reasons, even without being influenced by the recommendation of the
24
25 first prescriber. This would probably explain a large amount of the strong relationship
26
27 between hospital recommendation and pharmacy dispensation. Moreover, although
28
29 effects were adjusted for patient characteristics and vascular events during follow up,
30
31 there might be other unmeasured reasons for deciding upon a shorter DAPT period
32
33 facing an individual patient.
34
35
36
37
38
39
40

41
42 In addition, the recommendation at PCI hospital discharge may not coincide with the
43
44 final hospital prescription in patients derived to another reference hospital after PCI.
45
46 However, results of sensitivity analyses excluding these patients did not differ
47
48 substantially from the results of the main analyses.
49
50

51
52 The study was aimed to ascertain influence of guidelines on hospital recommendation
53
54 and its impact on patients' persistence with DAPT. The impact of persistence on
55
56 clinically relevant results is beyond the objective of the present study and will be
57
58 assessed in another article. Similarly, the study was not specifically aimed at a deep
59
60

1
2
3 assessment of determinants of adherence. This requires a detailed examination of the
4
5 social context and a detailed assessment of individual psychological factors[31].
6
7
8
9

10 **Conclusion**

11
12 The study shows that 12-month DAPT persistence in revascularized patients with
13 STEACS in Catalonia (Spain) has substantially increased between years 2010 to 2015
14 especially since one year after the publication of European guidelines in 2012.
15 Guidelines implementation was also followed by a substantial decrease in variability
16 between centres. We have shown that instructions given at the PCI hospital discharge
17 are strongly associated with persistence. Thus establishing common and rational
18 prescribing criteria between hospitals in the STEACS-network may favour patients
19 persistence with scheduled prescriptions and also reduce variability in clinicians'
20 practices.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

38 **Author contributions**

41 IFG, ARi, JRM conceived and designed the study; ARi, JRM and MTF participated in the
42 acquisition and analysis of data; HTM, SR, CL, MC, SH, CTQ, JGP, JAGH and MM were
43 responsible for data acquisition in their respective hospitals; ARi, IFG, JRM, GO, ARo,
44 JIP, JM and DGD were involved in the interpretation of results; ARi and IFG wrote the
45 manuscript and all other authors revised it critically and approved its final version
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The AMI-Code Registry Investigators (listed below) contribute to the functioning of the
AMI code and to data acquisition for the AMI-Code Registry:

1
2
3 C. Carvajal, P. Martínez, RM. Lidón, J. Bañeras (Hospital Universitari de la Vall
4
5 d'Hebrón, Barcelona), J. Garcia-Picart (Hospital de la Santa Creu i Sant Pau, Barcelona),
6
7
8 M. Massotti, G. Jiménez, M. Hernández, A. Regueiro (Hospital Clinic, Barcelona), J.
9
10 Basaganyas, P. Loma, M. Cardenas, E. Badosa, A. Fageda (Hospital Josep Trueta,
11
12 Girona) A. Ariza, C. García-Amigó, A. Cequier, A. Gómez-Hospital, G. Marín, J.
13
14 Maristany, V. Montoya (Hospital Universitari de Bellvitge, Hospitalet) , C. Labata, J.
15
16 Mauri, E. Fernández-Nofrerias, X. Carrillo, C. Garcia-Garcia, C. Oliete, (Hospital
17
18 Universitari Germans Trias i Pujol, Badalona) A. Bardaji, G. Bonet-Pineda, S. Rojas
19
20 (Hospital Joan XXIII, Tarragona). Juan F. Muñoz, F. Padilla, S. Homs (Hospital Mútua de
21
22 Terrassa, Terrassa), B. Baquerizo, L. Recasens, H. Tizon-Marcos (Hospital de Mar IMAS,
23
24 Barcelona), A. Bosch Gaya, F. Worner, L. Barta, M. Agustí, A. Gené (Hospital Arnau de
25
26 Vilanova, Lleida), X. Jimenez, A. Mora (Sistema d'Emergencies Mèdiques SEM SA,
27
28 Barcelona), MT. Faixedas, J. Jiménez, A. Rosas (Health Department. Generalitat de
29
30 Catalunya).

References

- 1 Steg PG, James SK, Atar D, *et al.* ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). *Eur Heart J* 2012;**33**:2569–619. doi:10.1093/eurheartj/ehs215
- 2 O’Gara PT, Kushner FG, Ascheim DD, *et al.* 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;**127**:e362–425. doi:10.1161/CIR.0b013e3182742cf6
- 3 Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med* 2005;**353**:487–97. doi:10.1056/NEJMra050100
- 4 Carrillo X, Fernandez-Nofrerias E, Rodriguez-Leor O, *et al.* Early ST elevation myocardial infarction in non-capable percutaneous coronary intervention centres: *in situ* fibrinolysis vs. percutaneous coronary intervention transfer. *Eur Heart J* 2016;**37**:1034–40. doi:10.1093/eurheartj/ehv619
- 5 Regueiro A, Bosch J, Martín-Yuste V, *et al.* Cost-effectiveness of a European ST-segment elevation myocardial infarction network: results from the Catalan Codi Infart network. *BMJ Open* 2015;**5**:e009148. doi:10.1136/bmjopen-2015-009148
- 6 Swieczkowski D, Mogielnicki M, Cwalina N, *et al.* Medication adherence in patients after percutaneous coronary intervention due to acute myocardial infarction: From research to clinical implications. *Cardiol J* 2016;**23**:483–90.

- 1
2
3 doi:10.5603/CJ.a2016.0048
4
5
6 7 Gislason GH, Rasmussen JN, Abildstrøm SZ, *et al.* Long-term compliance with
7
8 beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute
9
10 myocardial infarction. *Eur Heart J* 2006;**27**:1153–8.
11
12 doi:10.1093/eurheartj/ehi705
13
14
15 8 Kontopantelis E, Doran T, Springate DA, *et al.* Regression based quasi-
16
17 experimental approach when randomisation is not an option: Interrupted time
18
19 series analysis. *BMJ* Published Online First: 2015. doi:10.1136/bmj.h2750
20
21
22 9 Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the
23
24 evaluation of public health interventions: A tutorial. *Int J Epidemiol* Published
25
26 Online First: 2017. doi:10.1093/ije/dyw098
27
28
29
30 10 Yeh RW, Secemsky EA, Kereiakes DJ, *et al.* Development and Validation of a
31
32 Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year
33
34 After Percutaneous Coronary Intervention. *JAMA* 2016;**315**:1735.
35
36 doi:10.1001/jama.2016.3775
37
38
39
40 11 Yusuf S, Zhao F, Mehta SR, *et al.* Effects of Clopidogrel in Addition to Aspirin in
41
42 Patients with Acute Coronary Syndromes without ST-Segment Elevation. *N Engl J*
43
44 *Med* 2001;**345**:494–502. doi:10.1056/NEJMoa010746
45
46
47 12 Wiviott SD, Braunwald E, McCabe CH, *et al.* Prasugrel versus Clopidogrel in
48
49 Patients with Acute Coronary Syndromes. *N Engl J Med* 2007;**357**:2001–15.
50
51 doi:10.1056/NEJMoa0706482
52
53
54 13 Wallentin L, Becker RC, Budaj A, *et al.* Ticagrelor versus Clopidogrel in Patients
55
56 with Acute Coronary Syndromes. *N Engl J Med* 2009;**361**:1045–57.
57
58 doi:10.1056/NEJMoa0904327
59
60

- 1
2
3 14 Eisenstein EL, Anstrom KJ, Kong DF, *et al*. Clopidogrel Use and Long-term Clinical
4
5 Outcomes After Drug-Eluting Stent Implantation. *JAMA* 2007;**297**:159.
6
7 doi:10.1001/jama.297.2.joc60179
8
9
- 10 15 Bonaca MP, Bhatt DL, Cohen M, *et al*. Long-Term Use of Ticagrelor in Patients
11
12 with Prior Myocardial Infarction. *N Engl J Med* 2015;**372**:1791–800.
13
14 doi:10.1056/NEJMoa1500857
15
16
- 17 16 Mauri L, Kereiakes DJ, Yeh RW, *et al*. Twelve or 30 Months of Dual Antiplatelet
18
19 Therapy after Drug-Eluting Stents. *N Engl J Med* 2014;**371**:2155–66.
20
21 doi:10.1056/NEJMoa1409312
22
23
- 24 17 Levine GN, Bates ER, Bittl JA, *et al*. 2016 ACC/AHA Guideline Focused Update on
25
26 Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease:
27
28 A Report of the American College of Cardiology/American Heart Association
29
30 Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2016;**68**:1082–115.
31
32 doi:10.1016/j.jacc.2016.03.513
33
34
- 35 18 Tinetti ME, Bogardus ST, Agostini J V. Potential Pitfalls of Disease-Specific
36
37 Guidelines for Patients with Multiple Conditions. *N Engl J Med* 2004;**351**:2870–
38
39 4. doi:10.1056/NEJMsb042458
40
41
42
43
- 44 19 Kedhi E, Fabris E, van der Ent M, *et al*. Six months versus 12 months dual
45
46 antiplatelet therapy after drug-eluting stent implantation in ST-elevation
47
48 myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority
49
50 trial. *BMJ* 2018;**363**:k3793. doi:10.1136/bmj.k3793
51
52
53
- 54 20 Hahn J-Y, Song Y Bin, Oh J-H, *et al*. 6-month versus 12-month or longer dual
55
56 antiplatelet therapy after percutaneous coronary intervention in patients with
57
58 acute coronary syndrome (SMART-DATE): a randomised, open-label, non-
59
60

- 1
2
3 inferiority trial. *Lancet* 2018;**391**:1274–84. doi:10.1016/S0140-6736(18)30493-8
4
5
6 21 Bueno H, Pocock S, Danchin N, *et al.* International patterns of dual antiplatelet
7
8 therapy duration after acute coronary syndromes. *Heart* 2017;**103**:132–8.
9
10 doi:10.1136/heartjnl-2016-309509
11
12
13 22 Flather MD, Babalis D, Booth J, *et al.* Cluster-randomized trial to evaluate the
14
15 effects of a quality improvement program on management of non–ST-elevation
16
17 acute coronary syndromes: The European Quality Improvement Programme for
18
19 Acute Coronary Syndromes (EQUIP-ACS). *Am Heart J* 2011;**162**:700–707.e1.
20
21
22 doi:10.1016/j.ahj.2011.07.027
23
24
25 23 Czarny MJ, Nathan AS, Yeh RW, *et al.* Adherence to Dual Antiplatelet Therapy
26
27 After Coronary Stenting: A Systematic Review. *Clin Cardiol* 2014;**37**:505–13.
28
29
30 doi:10.1002/clc.22289
31
32
33 24 Green A, Pottegård A, Broe A, *et al.* Initiation and persistence with dual
34
35 antiplatelet therapy after acute myocardial infarction: A Danish nationwide
36
37 population-based cohort study. *BMJ Open* 2016;**6**. doi:10.1136/bmjopen-2015-
38
39 010880
40
41
42 25 Anastasius M, Lau JK, Hyun K, *et al.* The underutilisation of dual antiplatelet
43
44 therapy in acute coronary syndrome. *Int J Cardiol* 2017;**240**:30–6.
45
46
47 doi:10.1016/j.ijcard.2017.04.077
48
49
50 26 Prami T, Khanfir H, Deleskog A, *et al.* Clinical factors associated with initiation of
51
52 and persistence with ADP receptor-inhibiting oral antiplatelet treatment after
53
54 acute coronary syndrome: a nationwide cohort study from Finland. *BMJ Open*
55
56 2016;**6**:e012604. doi:10.1136/bmjopen-2016-012604
57
58
59 27 Varenhorst C, Jensevik K, Jernberg T, *et al.* Duration of dual antiplatelet
60

- 1
2
3 treatment with clopidogrel and aspirin in patients with acute coronary
4
5 syndrome. *Eur Heart J* 2014;**35**:969–78. doi:10.1093/eurheartj/eh438
6
7
- 8 28 Chung S-C, Sundström J, Gale CP, *et al*. Comparison of hospital variation in acute
9
10 myocardial infarction care and outcome between Sweden and United Kingdom:
11
12 population based cohort study using nationwide clinical registries. *Br Med J*
13
14 2015;**351**:h3913. doi:10.1136/BMJ.H3913
15
16
- 17 29 Eisenstein EL, Wojdyla D, Anstrom KJ, *et al*. Evaluating the impact of public
18
19 health notification: Duke clopidogrel experience. *Circ Cardiovasc Qual Outcomes*
20
21 2012;**5**:767–74. doi:10.1161/CIRCOUTCOMES.111.963330
22
23
24
- 25 30 Cabana MD, Rand CS, Powe NR, *et al*. Why don't physicians follow clinical
26
27 practice guidelines? A framework for improvement. *JAMA* 1999;**282**:1458–
28
29 65.<http://www.ncbi.nlm.nih.gov/pubmed/10535437> (accessed 28 Nov 2017).
30
31
- 32 31 Ferreira-Gonzalez I, Marsal JR, Ribera A, *et al*. Background, Incidence, and
33
34 Predictors of Antiplatelet Therapy Discontinuation During the First Year After
35
36 Drug-Eluting Stent Implantation. *Circulation* 2010;**122**:1017–25.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure legends**
4
5

6 Figure 1. Patients' flow chart
7
8

9
10 Figure 2. Observed 12-months persistence rate by quarter and interrupted time series
11
12 model specification after setting a one year lag period for guidelines implementation
13
14

15 Figure 3. Predicted probabilities of 12-months persistence by (A) drug eluting stent, (B)
16
17 recommendation pattern and (C) center, over time.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Patients flow

190x254mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Observed 12-months persistence rate by quarter and interrupted time series model specification after setting a one year lag period for guidelines implementation

127x127mm (300 x 300 DPI)




Figure 3. Predicted probabilities of 12-months persistence by (A) drug eluting stent, (B) recommendation pattern and (C) center, over time

127x304mm (300 x 300 DPI)

Supplemental methods

Data validation processes in the AMI Code registry

1. Automatic data validation processes to identify and feed-back missing data and incongruities.

2. Periodic data validation process every 3-6 months:

Since year 2011 this process was automated. The system automatically detects missing information in key variables and the identification of AMI codes that were activated by the emergency services (before admission) and were not included in the registry. Feed back for data validation is sent every 3-6 months for amendment or justification to the person responsible for data entry at each AMI Code Hospital.

Since year 2015 the automated process can be managed directly at any time by the person responsible for data entry in each hospital.

3. Specific studies:

In 2012 data were evaluated for **exhaustiveness**: all AMI cases consecutively admitted in 43 hospitals in Catalonia (10 AMI Code hospitals and 32 no AMI Code hospitals) during a 3 months period were registered and compared with the episodes registered in the AMI Code registry.

Between 88-92% of STEACS episodes were included in the AMI Code registry.

In 2013 concordance of the information between the AMI Code registry and the information from clinical records was assessed. 330 cases were analyzed and concordance was good for all key variables and there were no differences between hospitals.

1 **Supplemental tables**

2
3
4 Supplemental table 1. ICD9 codes used for the identification of conditions and diseases present at index
5
6 admission and for the identification of events during follow up.
7
8

9

Disease or condition	ICD9 diagnostic or procedure code
Heart failure	428.0, 428.1, 428.22, 428.23, 428.3, 428.32, 428.33, 428.41, 428.43
Renal disease	585*
Neoplasia	140-239
Anemia	280-285
Chronic obstructive pulmonary disease	491-492, 494*, 496*
Peripheral arterial disease	440.2, 440.3, 440.4
Atrial fibrillation	427.3*
Events during follow up	
Acute myocardial infarction	410*, except: 410.*2
Ischemic stroke	433*, 434*, except: 433.*0, 434.*0
Haemorrhagic stroke	430*, 431*, 432*
Intraocular bleeding	362.81, 363.6, 363.61, 363.62, 376.32, 377.42, 379.23
Digestive bleeding	530.21, 530.7, 530.82, 531.0, 531.2, 531.4, 531.6, 532.0, 532.2, 532.4, 532.6, 533.0, 533.2, 533.4, 534.4, 534.6, 535.01, 535.11, 535.21, 535.31, 535.41, 535.51, 535.61, 535.71, 537.83, 562.02, 562.03, 562.12, 562.13, 569.3, 569.85, 578.1, 578.9
Other bleeding	246.3, 459.0, 602.1, 784.8, 596.7, 599.7, 852*, 997.02, 998.1,
Endoscopic treatment	444.3, 454.2, 454.3
Transfusion	990.4

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Supplemental table 2. ATC codes used for the identification of drug treatment

Drug treatment	ATC code
ASA	B01AC06, N02BA01, B01AC30
Ticlopidine	B01AC05
Clopidogrel	B01AC04
Prasugrel	B01AC22
Ticagrelor	B01AC24
Dabigatran etexilate	B01AE07
Rivaroxaban	B01AF01
Apixaban	B01AF02
Beta-blocker	C07
ACE inhibitor	C09
Statins	C10AA


Supplemental table 3. Factors associated with a persistence of at least 12 months as assessed with interrupted time series logistic regression model. Results of sensitivity analyses.

Fixed Effects	Original Model			Discharged home			Non-ischemic or haemorrhagic events		
	OR	CI95%	P value	OR	CI95%	P value	OR	CI95%	P value
Drugeluting stent	2.02	1.61 - 2.53	<0.001	1.93	1.46 - 2.54	<0.001	2.045	1.66 - 2.53	<0.001
Number of Stents	1.21	1.12 - 1.31	<0.001	1.31	1.18 - 1.44	<0.001	1.231	1.14 - 1.33	<0.001
Recommendation at PCI hospital discharge (Ref. 1 month)									
<12 months	1.67	0.88 - 3.17	0.120	3.26	1.71 - 6.2	<0.001	2.016	0.96 - 4.26	0.066
≥12 months	5.92	3.34 - 10.52	<0.001	6.97	3.97 - 12.26	<0.001	7.443	4.19 - 13.23	<0.001
unknown	2.23	0.82 - 6.02	0.115	2.50	0.88 - 7.08	0.086	2.594	0.93 - 7.25	0.069
Hyperlipidemia	1.19	1.08 - 1.31	<0.001	1.14	1 - 1.3	0.045	1.222	1.11 - 1.35	<0.001
Previous by-pass surgery	1.81	1.06 - 3.07	0.029	2.69	1.3 - 5.58	0.008	1.838	1.01 - 3.34	0.045
Two or more treated vessels	1.20	1.09 - 1.32	<0.001	1.18	1.04 - 1.34	0.012	1.116	1.01 - 1.24	0.033
Drugeluting stents * Time (quarter)	0.97	0.95 - 0.98	<0.001	0.96	0.94 - 0.98	<0.001	0.963	0.95 - 0.98	<0.001
Guidelines implementation	1.20	1.11 - 1.3	<0.001	1.24	1.12 - 1.36	<0.001	1.238	1.14 - 1.35	<0.001
Recommendation at PCI hospital discharge (Ref. 1 month) * Time (quarter)*Guidelines implementation									
<12 months	0.91	0.8 - 1.05	0.191	0.87	0.73 - 1.03	0.097	0.904	0.79 - 1.04	0.160
≥12 months	0.87	0.8 - 0.94	0.001	0.85	0.76 - 0.94	0.002	0.845	0.77 - 0.92	<0.001
unknown	0.89	0.82 - 0.98	0.013	0.86	0.77 - 0.97	0.012	0.865	0.79 - 0.95	0.003
Random Effects	Var.	SD		Var.	SD		Var.	SD	
Random - Intercept	0.46	0.68		0.62	0.78		0.40	0.63	
Random - Slopes									
Recommendation at PCI hospital discharge (Ref. 1 month)	0.38	0.62		0.11	0.33		0.66	0.81	
<12 months	0.39	0.62		0.39	0.63		0.40	0.63	
≥12 months	2.00	1.41		2.16	1.47		2.12	1.46	
Drugeluting stent	0.09	0.30		0.13	0.35		0.07	0.27	
ICC	0.087			0.099			0.100		

Supplemental figure 1. Persistence with DAPT from discharge to 12 months by year of episode.



Supplemental figure 2. DAPT duration recommended in each hospital by year of episode



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page num
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3 (Design)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	7-8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	10-11
Study size	10	Explain how the study size was arrived at	9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	10-11 10-11 13 13 12
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	12 12 Fig 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	Tables 1, 2 Tables 1, 2 8
Outcome data	15*	Report numbers of outcome events or summary measures over time	Fig 1

			suppl
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 3
		(b) Report category boundaries when continuous variables were categorized	Table 3
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Table 3 suppl
Discussion			
Key results	18	Summarise key results with reference to study objectives	15
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	19-20
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	19-20
Generalisability	21	Discuss the generalisability (external validity) of the study results	20
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	5

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-Segment-Elevation Acute Coronary Syndrome. A population-based cohort study in Catalonia (Spain)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028114.R2
Article Type:	Research
Date Submitted by the Author:	19-Jun-2019
Complete List of Authors:	Ribera, Aida; University Hospital Vall d'Hebron, Cardiology Ferreira-Gonzalez, Ignacio; University Hospital Vall d'Hebron, Cardiology Marsal, Josep Ramon; University Hospital Vall d'Hebron, Cardiology Oristrell, Gerard; University Hospital Vall d'Hebron, Cardiology Faixedas, Maria Teresa; Servei Català de la Salut, Catalonia, Spain Rosas, Alba; 4. Departament de Salut, Generalitat de Catalunya Tizón-Marcos, Helena; 5. Cardiology Department, Hospital del Mar, and Heart Diseases Biomedical Research Group and IMIM (Hospital del Mar Medical Research Institute), and Faculty of Medicine, Universitat Autonoma de Barcelona Rojas, Sergio; 6. Cardiology Department, Hospital Universitari de Tarragona Joan XXIII, IISPV, and Universidad Rovira Virgili Labata, Carlos; Cardiology Department, Hospital German Tries i Pujol Cardenas, Merida; Cardiology Department, Hospital Josep Trueta Homs, Silvia; Cardiology Department, Hospital Mútua de Terrassa Tomas-Querol, Carlos; Cardiology Department, Hospital Arnau de Villanova Garcia-Picart, Joan; 11. Cardiology Department, Hospital de la Santa Creu i Sant Pau Gomez-Hospital, Joan; Cardiology Department, Hospital de Bellvitge Pijoan, Jose; BioCruces Health Research Institute Masotti, Monica; Cardiology Department, Hospital Clínic Mauri, Josepa; Departament de Salut, Generalitat de Catalunya Garcia Dorado, David; University Hospital Vall d'Hebron, Cardiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Health services research
Keywords:	dual antiplatelet therapy, ST-elevation myocardial infarction, persistence with treatment, percutaneous coronary intervention

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **Persistence with dual antiplatelet therapy after percutaneous coronary intervention**
4 **for ST-Segment-Elevation Acute Coronary Syndrome. A population-based cohort**
5 **study in Catalonia (Spain)**
6
7
8
9

10
11 Aida Ribera^{1,2}, PhD; Ignacio Ferreira-González^{1,2}, MD PhD; Josep Ramon Marsal^{1,2}, PhD;
12
13 Gerard Oristrell^{1,2}, MD Maria Teresa Faixedas³, MD; Alba Rosas⁴, PhD; Helena Tizón-
14
15 Marcos⁵, MD; Sergio Rojas⁶, MD; Carlos Labata⁷, MD; Mérida Cárdenas⁸, MD; Silvia
16
17 Homs⁹, MD; Carlos Tomás-Querol¹⁰, MD; Joan Garcia-Picart¹¹, MD; Joan A. Gomez-
18
19 Hospital¹², MD, PhD; Jose Ignacio Pijoan^{2,13}, MD PhD; Monica Masotti¹⁴, MD; Josepa
20
21 Mauri^{4,7}, MD PhD; David García-Dorado¹, MD PhD
22
23
24
25

26 On behalf of the VESA Study and Codi IAM Investigators

- 27
28 1. Cardiology Department, Vall d'Hebrón Hospital, Vall d'Hebron Research
29
30 Institute (VHIR) and Universitat Autònoma de Barcelona. Barcelona, Spain
31
32 2. CIBER de Epidemiología y Salud Pública (CIBERESP). Spain
33
34 3. Servei Català de la Salut, Catalonia, Spain
35
36 4. Departament de Salut, Generalitat de Catalunya, Catalonia, Spain.
37
38 5. Cardiology Department, Hospital del Mar, and Heart Diseases Biomedical
39
40 Research Group and IMIM (Hospital del Mar Medical Research Institute), and
41
42 Faculty of Medicine, Universitat Autònoma de Barcelona. Spain
43
44 6. Cardiology Department, Hospital Universitari de Tarragona Joan XXIII, IISPV,
45
46 and Universidad Rovira Virgili. Tarragona. Spain.
47
48 7. Cardiology Department, Hospital German Tries i Pujol. Barcelona. Spain.
49
50 8. Cardiology Department, Hospital Josep Trueta. Girona. Spain.
51
52 9. Cardiology Department, Hospital Mútua de Terrassa. Bcelona. Spain.
53
54 10. Cardiology Department, Hospital Arnau de Villanova. Lleida. Spain.
55
56
57
58
59
60

1
2
3 11. Cardiology Department, Hospital de la Santa Creu i Sant Pau. Barcelona. Spain.
4

5 12. Cardiology Department, Hospital de Bellvitge. Barcelona. Spain
6

7
8 13. Clinical Epidemiology Unit, Hospital Universitario Cruces/BioCruces Health
9
10 Research Insitute, Bilbao. Spain
11

12
13 14. Cardiology Department, Hospital Clínic, Barcelona. Spain.
14
15
16
17

18
19 **Corresponding author**

20
21
22 Ignacio Ferreira-González. Cardiovascular Epidemiology Unit. Cardiology Department.
23

24 University Hospital Vall d'Hebron. Psg. Vall d'Hebron, 119-129 08035 Barcelona. Spain
25

26
27 nachoferreira@secardiologia.es
28

29 tel. 932746177
30
31
32
33

34 **Word count:** 4013
35

36 **Keywords:** dual antiplatelet therapy, persistence with treatment, ST-elevation
37
38 myocardial infarction, percutaneous coronary intervention
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Guidelines recommending 12 months dual antiplatelet therapy (DAPT) in patients with ST-elevation acute coronary syndrome (STEACS) undergoing percutaneous coronary intervention (PCI) were published in year 2012. We aimed to describe the influence of guideline implementation on the trend in 12-month persistence with DAPT between 2010 and 2015 and to evaluate its relationship with DAPT duration regimens recommended at discharge from PCI hospitals.

Design: Observational study based on region-wide registry data linked to pharmacy billing data for DAPT follow up.

Setting. All PCI hospitals (10) belonging to the AMI-Code network in Catalonia (Spain)

Participants: 10,711 STEACS patients undergoing PCI between 2010 and 2015 were followed up.

Primary and secondary outcome measures: Primary outcome was 12 month persistence with DAPT. Calendar year quarter, publication of guidelines; DAPT duration regimen recommended in the hospital discharge report, baseline patient characteristics and significant interactions were included in mixed effects logistic regression based interrupted time-series models. **Results:** The proportion of patients on-DAPT at 12 months increased from 58% (56-60) in 2010 to 73% (71-75) in 2015. The rate of 12-months persistence with DAPT significantly increased after the publication of clinical guidelines with a time lag of one year (OR=1.20; 95% CI: 1.11-1.30). A higher risk profile, more extensive and complex coronary disease, use of drug-eluting stents (OR=1.90; 95% CI: 1.50-2.40) and a 12-months DAPT regimen recommendation at discharge from the PCI hospital (OR=5.76; 95% CI: 3.26-10.2) were associated with 12-months persistence.

1
2
3 **Conclusion:** Persistence with 12-month DAPT has increased since publication of clinical
4
5 guidelines. Even though most patients were discharged on DAPT, only 73% with
6
7 potential indication were on-DAPT 12 months after PCI. A guideline-based
8
9 recommendation at PCI hospital discharge was highly associated with full persistence
10
11 with DAPT. Establishing evidence-based, common prescribing criteria across hospitals
12
13 in the AMI-network would favour adherence and reduce variability.
14
15
16
17
18
19
20

21 **Strengths and limitations of this study**

- 22
- 23 • The study describes the trends in persistence with DAPT during 2010-2015 in a
- 24 region-wide comprehensive cohort of patients using administrative data linked
- 25 to a clinical registry
- 26
- 27
- 28
- 29
- 30
- 31 • It also evaluates the impact of the DAPT duration recommended at the PCI
- 32 hospital discharge on 12-months persistence
- 33
- 34
- 35
- 36 • Limitations of using observational registry data include the possibility of coding
- 37 errors and the inability to accurately identify specific contraindications for
- 38 treatment or other patient characteristics that might be relevant for the study
- 39 aims
- 40
- 41
- 42
- 43
- 44
- 45
- 46 • The use of pharmacy refill data as a proxy of patients' adherence and
- 47 persistence has also limitations which have been extensively described
- 48
- 49
- 50
- 51
- 52
- 53

54 **Study funding**

55
56
57
58
59
60

1
2
3 The study was supported by Instituto de Salud Carlos III grand number PI13/00399 and
4
5 the Fundació la Marató de TV3 grand number 430/U/2015. The funders did not have
6
7 any role in the study design and development.
8
9

10 11 **Competing interest statement** 12

13
14 All authors have completed the ICMJE uniform disclosure form at
15
16 http://www.icmje.org/coi_disclosure.pdf and declare: no support from any
17
18 organisation for the submitted work; no financial relationships with any organisations
19
20 that might have an interest in the submitted work in the previous three years, no other
21
22 relationships or activities that could appear to have influenced the submitted work
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The need of dual antiplatelet therapy (DAPT) combining aspirin and an ADP-receptor blocker for at least 12 months in patients with ST-elevation acute coronary syndrome (STEACS) undergoing percutaneous coronary intervention (PCI) is well established and was incorporated into clinical guidelines in 2012[1,2].

Adherence of patients to this strategy is crucial to ensure its efficacy. Adherence to medication is usually defined[3] as the extent to which patients take medications as prescribed by their health care providers and persistence is defined as time from initiation to discontinuation of a therapy. Patients' persistence with DAPT may be influenced by several factors but will depend strongly on whether they ultimately receive a correct prescription from their physicians in the primary care setting. Patients may receive recommendations from various health providers at different stages of their process of care, from the interventionist cardiologist to their primary physician. It could be hypothesized that the last would tend to rely on the recommendation of the more specialized health professional. Thus, one potential determinant of patients' persistence with DAPT for at least 12 months is the instructions provided in the discharge report of the hospital where the patient was attended during the acute phase.

In Catalonia, an autonomous region of Spain, the acute care of STEACS is organized through a region-wide network, the Acute Myocardial Infarction (AMI) Code, to derive patients with suspected STEACS to one of the 10 reference hospitals with PCI

1
2
3 capability. Performance of the AMI Code is prospectively and exhaustively
4 registered[4,5], providing an appropriate tool for quality evaluation. The Catalan
5 Health Information System systematically registers, among other, data on pharmacy
6 refills. Pharmacy billing data, although indirect, is an accepted method for evaluating
7 persistence with treatment in large patient cohorts[3,6].
8
9
10
11
12
13
14
15
16
17

18 The aims of the present study were: first, to describe persistence with DAPT for at least
19 12 months in patients with STEACS undergoing PCI from 2010 to 2015; second, to
20 evaluate the influence guidelines recommendation for a 12-months DAPT schedule on
21 the rate of 12-months persistence along time; and third, to evaluate the association of
22 the DAPT duration recommended at the PCI hospital discharge with patients'
23 persistence with treatment for at least 12 months.
24
25
26
27
28
29
30
31
32
33
34

35 **Methods**

36 ***Data sources***

37
38
39
40
41 Data were obtained through the Public Data Analysis for Health Research and
42 Innovation Program (PADRIS). The PADRIS allows access to information from different
43 sources on public healthcare resources usage for the population of Catalonia linked at
44 the patient level with warranted accomplishment of ethical principles. Specifically, for
45 the present study we linked data of the pharmacy billing registry with the AMI Code
46 Registry. The AMI Code registry was launched in 2010 to evaluate performance of the
47 AMI Code [4,5]. Exhaustiveness and quality of data is assessed periodically (see
48 supplemental methods for details). The database belongs to the Catalan Department
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of Health and includes demographic, clinical, and therapeutic data for each episode of
4
5 hospitalization for STEACS. It conforms to the ethical and legal requirements for
6
7 research purposes. The study obtained ethics approval from the Vall d'Hebron Clinical
8
9 Research Ethics Committee (EPA(AG)7/2014(3989)).
10
11
12
13
14

15 The registry was completed for the purpose of the present analysis with retrospective
16
17 collection of additional specific data: diseased vessels, responsible vessel, stent type,
18
19 number of stents. The recommendation of antithrombotic drugs was also collected *ad*
20
21 *hoc* for the study from the discharge report. The recommendation of DAPT was
22
23 defined as the recommendation of Acetylsalicylic acid (ASA) and clopidogrel, prasugrel
24
25 or ticagrelor for specified periods. If the recommended duration of DAPT was not
26
27 specified, the discharge recommendation pattern was classified as "unspecified". A
28
29 local investigator at each center performed the specific retrospective data collection.
30
31
32
33

34 History of major haemorrhage, neoplasia, renal disease, heart failure, peripheral
35
36 arterial disease and atrial fibrillation, were obtained from minimum basic data set
37
38 (MBDS) diagnoses coded in hospitalization episodes occurring in the previous three
39
40 months before index hospitalization. Major haemorrhage was defined as: a diagnosis
41
42 of digestive bleeding in any diagnostic position (primary or secondary) together with a
43
44 procedure code for endoscopic treatment or for transfusion of blood products, or a
45
46 diagnosis of haemorrhagic stroke, or a diagnosis of intraocular haemorrhage, or a
47
48 diagnosis of other types of haemorrhage together with a procedure code for
49
50 transfusion of blood products. Major ischemic events (AMI or stroke) and major
51
52 haemorrhage during the 12 months following the index episode were obtained in the
53
54
55
56
57
58
59
60

1
2
3 same way. Mortality during the 12 months following the index episode was obtained
4
5 from the insured registry status.
6
7

8
9 Drug treatment during the 12-month post-discharge follow up was obtained from the
10
11 pharmacy billing registry. ICD9 and ATC codes used for the identification of study
12
13 variables are listed in the supplemental tables 1 and 2.
14
15
16

17 18 19 20 ***Data Availability Statement*** 21

22
23 Additional data is not available due to ethical requirements of the PADRIS Program
24
25
26
27
28

29 30 ***Study population*** 31

32 We included all consecutive patients who survived a STEACS between January 2010
33
34 and December 2015, received primary or post fibrinolysis PCI in one of the 10
35
36 reference hospitals of the AMI Code network, were discharged home or transferred to
37
38 another hospital and survived at least one month after AMI. New episodes of STACS
39
40 occurring to the same patients during the study period were only accounted as follow
41
42 up events. Patients with likely contraindication for DAPT (history of major bleeding or
43
44 neoplasm in the three months prior to the index episode and patients requiring
45
46 anticoagulation) were excluded.
47
48
49
50
51
52

53 54 ***Persistence with treatment*** 55

56 DAPT was defined as the concomitant use of ASA and a P2Y₁₂ antagonist. Persistence
57
58 with DAPT was estimated by identification of consecutive months with pharmacy refills
59
60

1
2
3 with one container of each agent in the 12-month period after hospital discharge.
4
5 Because pharmacy billing is registered in a monthly basis and the exact day of
6 dispensation is unknown, we considered that a monthly dispensation until at least
7
8 month 11 after the index episode would approximate a 12-months treatment period. If
9
10 more than one container were dispensed in one month, the excess containers were
11
12 pulled along the following months. Non-persistence was defined as either
13
14 discontinuation or a break in therapy of at least two months after pulling along the
15
16 excess containers. To describe persistence over the whole study period we estimated
17
18 the proportion of patients alive and within the 12 months after discharge window who
19
20 were on treatment on each month[7].
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

The primary outcome was a patient's persistence with DAPT for 12 months following discharge (or in other words, patients withdrawing both agents from the pharmacy until at least month 11).

Statistical analysis

38
39
40 We compared baseline characteristics between patients persisting with DAPT for at
41
42 least 12 months and patients withdrawing DAPT before 12 months with chi square test
43
44 or t test when appropriate. We tested for trends in patients' characteristics along
45
46 calendar year of discharge for the index procedure with Jonckheere-Terpstra test for
47
48 differences between ordered categories.
49
50
51
52
53
54

55 To evaluate the influence of time, guidelines publication and the DAPT duration
56
57 recommended in the PCI hospital discharge report we modelled logistic regression
58
59 based interrupted time-series analysis[8], adjusting for baseline characteristics. As a
60

1
2
3 first step, because it is expected that guidelines publication influences practice with a
4 time delay, we plotted the proportion of patients persisting on-DAPT for 12 months by
5 year quarter of discharge from the PCI hospital and we tested models with a slope
6 change (indicating the start of guideline implementation) at different lag periods after
7 publication of the European clinical guidelines (last quarter of 2012). Once the lag
8 period between guidelines publication and implementation of recommendations was
9 estimated we included patient characteristics and second or third level interactions of
10 each characteristic with year quarter and moment of implementation. We also
11 included an autocorrelation term. We coded time (T) as the time elapsed since the
12 publication of guidelines plus the lag period (in quarters) and a dummy variable (X_t)
13 indicating the pre-implementation period (coded 0) or the post-implementation period
14 (coded 1)[9].

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35 The standard model specification was the following:

$$\text{logit}(Y_t) = \beta_0 + \beta_1 T + \beta_2 X_t + \beta_3 T X_t$$

36
37
38
39
40
41
42 Where β_0 represents the baseline level at $T = 0$, β_1 is interpreted as the change in
43 outcome associated with a time unit (quarter) increase (representing the underlying
44 pre-implementation trend), β_2 is the level change following the implementation and
45 β_3 indicates the slope change following the implementation (using the interaction
46 between time and implementation: $T X_t$). Additional terms can be added to model the
47 effect of other covariables and their interactions with T and X_t and to include random
48 effects. Note that we set $T = 0$ at the quarter where we observed a significant change
49 in the slope at a lag time after guidelines publication.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 We took into account the clustered structure of data with patients being treated and,
6
7
8 most importantly, with recommendations on DAPT duration being provided in
9
10 different hospitals, by introducing random effects in the logistic regression models.

11
12 We tested whether models including random intercepts for hospital and random
13
14 slopes for each independent variable were significant using a deviance-based test of
15
16 hypothesis.
17
18

19
20
21
22 Variable selection for multilevel modelling was based on the bivariate associations
23
24 with the rate of each dependent variable. Candidate individual variables were those
25
26 described in tables 1 and 2. We retained in the final model all variables with a p
27
28 value < 0.2.
29
30

31
32 Plots of predicted probability values were used to show marginal effects of variables of
33
34 interest and variability between centres.
35
36

37 38 39 ***Sensitivity analyses***

40
41 Because a substantial proportion of patients were returned to their reference hospital
42
43 and because it was unknown whether the DAPT duration recommendation was
44
45 changed at discharge from the second hospital, we performed sensitivity analyses
46
47 excluding these patients. Additionally, because ischemic and haemorrhagic events
48
49 occurring during follow up would change the treatment length, sensitivity analyses
50
51 were also performed by excluding patients suffering any vascular event during follow
52
53 up.
54
55
56
57

58 59 ***Patient and Public Involvement***

60

Neither patients nor public were directly involved in the study.

Results

After excluding patients with likely contraindication for DAPT (figure 1), we identified 10,711 STEACS patients undergoing PCI who were potential candidates to receive DAPT for at least 12 months and survived for at least one month after discharge. 631 (5.9%) patients experienced an ischemic major event (AMI or stroke) within 12 months after the index episode, 100 (0.9%) had a major haemorrhage and 280 (2.6%) died between one and 12 months after the index episode. After excluding patients who died or were lost to follow up and patients with errors in quarter allocations, 10,262 patients remained for analysis.

Table 1 shows characteristics of study patients depending on persistence with DAPT. Patients persisting for at least 12 months had higher prevalence of cardiovascular risk factors (hypertension, diabetes and hypercholesterolemia), higher rate of a previous history of cardiovascular disease, more extended coronary disease, higher rate of drug eluting stents implantation and slightly higher ischemic risk (as measured with the DAPT score[10]). Persisting patients were more often transferred to their reference hospital and had had a prescription for a longer DAPT period at discharge from the PCI hospital.

Table 1. Characteristics of study patients according to DAPT persistence during follow up.

	DAPT <12 months (n=3684)		DAPT ≥ 12 months (n=6578)		Total (n=10262)		P value
	N	n (%)	N	n (%)	N	n (%)	
Age	3684	61.19 ± 13.21	6578	61.18 ± 12.38	10262	61.19 ± 12.69	0.578

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Gender (Female)	3684	765 (20.8%)	6578	1319 (20.1%)	10262	2084 (20.3%)	0.399
Smoke (Y)	3684	1774 (48.2%)	6578	3042 (46.2%)	10262	4816 (46.9%)	0.064
Hypertension (Y)	3684	1622 (44%)	6578	3142 (47.8%)	10262	4764 (46.4%)	<0.001
Diabetes (Y)	3684	647 (17.6%)	6578	1298 (19.7%)	10262	1945 (19%)	0.008
Hypercholesterolaemia (Y)	3684	1291 (35%)	6578	2678 (40.7%)	10262	3969 (38.7%)	<0.001
Polyvascular disease (Y)*	3684	530 (14.4%)	6578	1048 (15.9%)	10262	1578 (15.4%)	0.038
Previous stroke or transient ischaemic attack (Y)	3684	101 (2.7%)	6578	172 (2.6%)	10262	273 (2.7%)	0.704
Previous acute myocardial infarction (Y)	3684	265 (7.2%)	6578	570 (8.7%)	10262	835 (8.1%)	0.010
Previous percutaneous coronary intervention (Y)	3684	194 (5.3%)	6578	482 (7.3%)	10262	676 (6.6%)	<0.001
Previous by-pass surgery (Y)	3684	20 (0.5%)	6578	85 (1.3%)	10262	105 (1%)	<0.001
History of peripheral arteriopathy (Y)	3684	153 (4.2%)	6578	276 (4.2%)	10262	429 (4.2%)	0.957
Comorbidity (Y)†	3684	462 (12.5%)	6578	885 (13.5%)	10262	1347 (13.1%)	0.191
Hepatopathy (Y)	3684	48 (1.3%)	6578	56 (0.9%)	10262	104 (1%)	0.030
History of Renal Impairment (Y)	3684	185 (5%)	6578	320 (4.9%)	10262	505 (4.9%)	0.741
History of Heart Failure (Y)	3684	272 (7.4%)	6578	583 (8.9%)	10262	855 (8.3%)	0.009
Affected number of vessels ≥2 (Y)	3684	1275 (34.6%)	6578	2731 (41.5%)	10262	4006 (39%)	<0.001
Number of treated vessels	3613	1.03 ± 0.21	6516	1.06 ± 0.26	10129	1.05 ± 0.25	<0.001
Number of stents	3681	1.09±0.6	6563	1.21±0.68	10244	1.16±0.65	<0.001
Drug eluting stent (Y)	3684	572 (15.5%)	6578	2704 (41.1%)	10262	3276 (31.9%)	<0.001
DAPT Score Points	3684	1.20 ± 1.20	6578	1.28 ± 1.17	10262	1.25 ± 1.18	<0.001
Discharged home (Y)	3684	2233 (60.6%)	6578	3672 (55.8%)	10262	5905 (57.5%)	<0.001
Antiplatelet agent at discharge	3684		6578		10262		<0.001
Clopidogrel		3184 (86.4%)		4872 (74.1%)		8056 (78.5%)	
Prasugrel		278 (7.5%)		1102 (16.8%)		1380 (13.4%)	
Ticagrelor		222 (6%)		604 (9.2%)		826 (8%)	
DAPT recommendation at discharge	3684		6578		10262		<0.001
1 month		875 (23.8%)		295 (4.5%)		1170 (11.4%)	
<12 months		385 (10.5%)		173 (2.6%)		558 (5.4%)	
≥12months		1522 (41.3%)		4732 (71.9%)		6254 (60.9%)	
unknown		902 (24.5%)		1378 (20.9%)		2280 (22.2%)	

*Polyvascular disease was defined as presence of at least two of the following conditions: previous myocardial infarction or percutaneous coronary or surgical revascularization; history of peripheral arteriopathy; history of stroke or transient ischaemic attack. †Comorbidity was defined as presence of one of the following conditions: hepatopathy, history of renal impairment, history of heart failure

1
2
3 The rate of patients on-DAPT after discharge from the PCI hospital was 91% (95% CI:
4 90-91) without relevant differences between years (supplemental figure 1). The
5
6 proportion of patients on-DAPT at 12 months significantly increased from 58% (56-61)
7
8 in 2010 to 73% (71-75) in 2015. The larger increase in 12-month persistence was
9
10 observed between 2014 (64% [62-66]) and 2015, two years after the publication of
11
12 clinical guidelines. The proportion of patients with prasugrel or ticagrelor instead of
13
14 clopidogrel started increasing after 2012 (supplemental figure 2).
15
16
17
18
19
20
21
22

23 Some baseline characteristics showed a temporal trend over the study period 2010-
24
25 2015 (table 2). The prevalence of cardiovascular risk factors (smoking, hypertension
26
27 and hypercholesterolemia) and comorbidities increased slightly. Likewise, the number
28
29 of treated vessels the rate of drug eluting stents implantation and the rate of prasugrel
30
31 or ticagrelor also increased with time.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Characteristics of study patients by year of discharge for the index admission.

	2010 (n=1537)	2011 (n=1628)	2012 (n=1760)	2013 (n=1779)	2014 (n=1779)	2015 (n=1779)	P value
Age	61 ± 12.92	61.01 ± 13.09	60.97 ± 12.52	61.27 ± 12.4	61.24 ± 12.72	61.58 ± 12.53	0.325
Gender	310 (20.2%)	311 (19.1%)	372 (21.1%)	359 (20.2%)	352 (19.8%)	380 (21.4%)	0.389
Smoke	686 (44.6%)	754 (46.3%)	811 (46.1%)	839 (47.2%)	840 (47.2%)	886 (49.8%)	0.004
Hypertension	674 (43.9%)	729 (44.8%)	808 (45.9%)	838 (47.1%)	844 (47.4%)	871 (49%)	0.001
Diabetes	296 (19.3%)	319 (19.6%)	340 (19.3%)	327 (18.4%)	325 (18.3%)	338 (19%)	0.438
Hypercholesterolaemia	541 (35.2%)	621 (38.1%)	648 (36.8%)	710 (39.9%)	742 (41.7%)	707 (39.7%)	<0.001
Polyvascular disease*	232 (15.1%)	253 (15.5%)	301 (17.1%)	259 (14.6%)	278 (15.6%)	255 (14.3%)	0.370
Previous stroke or transient ischaemic attack	42 (2.7%)	32 (2%)	45 (2.6%)	40 (2.2%)	65 (3.7%)	49 (2.8%)	0.126
Previous acute myocardial infarction	127 (8.3%)	142 (8.7%)	163 (9.3%)	151 (8.5%)	127 (7.1%)	125 (7%)	0.029
Previous percutaneous coronary intervention	94 (6.1%)	104 (6.4%)	123 (7%)	116 (6.5%)	118 (6.6%)	121 (6.8%)	0.485
Previous by-pass surgery	10 (0.7%)	16 (1%)	17 (1%)	19 (1.1%)	18 (1%)	25 (1.4%)	0.056
History of peripheral arteriopathy	51 (3.3%)	70 (4.3%)	93 (5.3%)	66 (3.7%)	86 (4.8%)	63 (3.5%)	0.876
Comorbidity†	155 (10.1%)	190 (11.7%)	233 (13.2%)	243 (13.7%)	266 (15%)	260 (14.6%)	<0.001
Hepatopathy	16 (1%)	12 (0.7%)	24 (1.4%)	24 (1.3%)	13 (0.7%)	15 (0.8%)	0.578
History of Renal Impairment	70 (4.6%)	75 (4.6%)	71 (4%)	86 (4.8%)	89 (5%)	114 (6.4%)	0.009
History of Heart Failure	80 (5.2%)	118 (7.2%)	154 (8.8%)	159 (8.9%)	187 (10.5%)	157 (8.8%)	<0.001
Affected number of vessels ≥2	594 (38.6%)	617 (37.9%)	679 (38.6%)	707 (39.7%)	688 (38.7%)	721 (40.5%)	0.188
Number of treated vessels	1.04 ± 0.25	1.03 ± 0.23	1.05 ± 0.26	1.05 ± 0.24	1.05 ± 0.26	1.06 ± 0.24	0.003
Number of stents	1.23 ± 0.69	1.17 ± 0.60	1.18 ± 0.63	1.14 ± 0.66	1.12 ± 0.67	1.16 ± 0.66	<0.001
Drug eluting stent	462 (30.1%)	388 (23.8%)	472 (26.8%)	493 (27.7%)	652 (36.6%)	809 (45.5%)	<0.001
DAPT Score Points	1.24 ± 1.2	1.24 ± 1.19	1.26 ± 1.17	1.26 ± 1.17	1.22 ± 1.16	1.28 ± 1.19	0.435
Discharged home	961 (62.5%)	951 (58.4%)	933 (53%)	1042 (58.6%)	959 (53.9%)	1059 (59.5%)	0.041
Antiplatelet agent at discharge							<0.001
Clopidogrel	1528 (99.4%)	1587 (97.5%)	1582 (89.9%)	1384 (77.8%)	1114 (62.6%)	861 (48.4%)	
Prasugrel	9 (0.6%)	38 (2.3%)	135 (7.7%)	244 (13.7%)	416 (23.4%)	538 (30.2%)	

	2010 (n=1537)	2011 (n=1628)	2012 (n=1760)	2013 (n=1779)	2014 (n=1779)	2015 (n=1779)	P value
Ticagrelor	0 (0%)	3 (0.2%)	43 (2.4%)	151 (8.5%)	249 (14%)	380 (21.4%)	
DAPT recommendation at discharge							<0.001
1 month	281 (18.3%)	259 (15.9%)	243 (13.8%)	181 (10.2%)	135 (7.6%)	71 (4%)	
<12 months	150 (9.8%)	137 (8.4%)	100 (5.7%)	69 (3.9%)	65 (3.7%)	37 (2.1%)	
≥12 months	792 (51.5%)	871 (53.5%)	975 (55.4%)	1086 (61%)	1154 (64.9%)	1376 (77.3%)	
unknown	314 (20.4%)	361 (22.2%)	442 (25.1%)	443 (24.9%)	425 (23.9%)	295 (16.6%)	

*Polyvascular disease was defined as presence of at least two of the following conditions: previous myocardial infarction or percutaneous coronary or surgical revascularization; history of peripheral arteriopathy; history of stroke or transient ischaemic attack. †Comorbidity was defined as presence of one of the following conditions: hepatopathy, history of renal impairment, history of heart failure

1
2
3
4
5 The overall rate of explicit DAPT recommendation for at least 12 months in the
6 hospital discharge reports was 51% (49-53) in 2010 and increased to 77% (75-79) in
7
8
9
10 2015 but it was highly variable between hospitals (supplemental figure 3).

11
12
13
14
15 Figure 2 shows the observed proportion of patients persisting with DAPT for at least 12
16 months at each time point and the interrupted time series model fitted after setting a
17
18
19
20 one year lag period from publication to implementation of guidelines.
21
22

23
24
25 Table 3 shows results of the complete cases analysis (n=10,244) using interrupted time
26 series logistic regression. Variables showing association with 12 month persistence on
27
28
29
30 DAPT were two or more diseased vessels, higher number of stents implanted, receiving
31
32
33 drug eluting stents, hypercholesterolemia, a previous surgical procedure, taking
34
35 prasugrel instead of clopidogrel and a recommendation of DAPT for a longer period at
36
37 discharge from the PCI hospital. Autocorrelation was not significant. Guideline
38
39 implementation had a positive effect on persistence: a 20% increase in the odds of 12
40
41
42 month persistence each quarter after a lag of one year since publication. The effect of
43
44
45 drug eluting stents was attenuated with time (OR for interaction: 0.96; 95%CI: 0.94-
46
47 0.97) while the effect of prescription was attenuated with time after guideline
48
49 implementation (OR for the interaction 0.86, 95%CI: 0.79-0.94 for a recommendation
50
51 of ≥ 12 months and 0.88, 95%CI: 0.81-0.97 for an unknown recommendation). The
52
53
54 effect of implantation of drug eluting stents and type of recommendation also varied
55
56
57 between hospitals (significant random slopes).
58
59
60

Table 3. Factors associated with a persistence of at least 12 months as assessed with interrupted time series logistic regression model

Fixed effects	OR	95% CI	P value
Drug eluting stent	1.90	1.50 - 2.40	<0.001
Number of stents	1.22	1.13 - 1.32	<0.001
Antiplatelet agent at discharge (Ref. Clopidogrel)			
Prasugrel	1.59	0.88 – 1.26	<0.001
Ticagrelor	1.05	1.36 – 1.86	0.575
Recommendation at PCI hospital discharge (Ref. 1 month)			
<12 months	1.67	0.89 - 3.14	0.110
≥12 months	5.76	3.26 - 10.2	<0.001
unknown	2.25	0.84 - 6.01	0.107
Hypercholesterolemia	1.19	1.08 - 1.31	<0.001
Previous by-pass surgery	1.85	1.09 - 3.14	0.023
Two or more treated vessels	1.21	1.10 - 1.33	<0.001
Drug eluting stent * Time (quarter)	0.96	0.94 - 0.97	<0.001
Guideline implementation	1.20	1.11 - 1.30	<0.001
Recommendation at PCI hospital discharge (Ref. 1 month) * Time (quarter)*Guideline implementation			
<12 months	0.90	0.79 - 1.04	0.144
≥ 12 months	0.86	0.79 - 0.94	<0.001
unknown	0.88	0.81 - 0.97	0.007
Random effects	Variance	95% CI	
Random - Intercept	0.46	0.22 – 1.53	
Random - Slopes			
Recommendation at PCI hospital discharge (Ref. 1 month)			
<12 months	0.37	0.17 – 1.23	
≥12 months	0.39	0.19 – 1.31	
unknown	1.97	0.93 – 6.58	
Drug eluting stent	0.10	0.05 – 0.33	
Adjusted ICC	0.085		

Results of sensitivity analyses, excluding patients with ischemic or haemorrhagic events during follow up, or excluding patients that were transferred to another centre after PCI were similar to the main analysis (Supplemental table 3S).

The interaction between drug eluting stents and time can be seen in figure 3A. Because 12-months persistence increased with time in patients without drug eluting

1
2
3 stents, the effect of type of stent is attenuated with time. The interaction of the
4
5 recommendation pattern with time and guideline implementation can be seen in
6
7 figure 3B: 12-months persistence increased with time mainly in the subgroups with
8
9 shorter time specification in the discharge report and also in patients without a specific
10
11 recommendation, but this increase started after guideline implementation (one year
12
13 after publication). Figure 3C shows a substantial reduction in the variability between
14
15 centres mainly due to an increase in the proportion of 12-months persistence in
16
17 patients attended in centres where the initial proportion was lower (significant
18
19 random intercept and slopes).
20
21
22
23
24
25
26
27

28 Discussion

29
30 According to published guidelines, all STEACS patients undergoing PCI without
31
32 contraindication should be kept on DAPT for at least 12 months unless an event occurs
33
34 that precludes continuing with this treatment. In this observational region-wide study
35
36 we have found an increase in the proportion of patients on-DAPT at 12 months from
37
38 58 to 73% in the period from 2010 to 2015, with an accelerated rate starting in the
39
40 fourth quarter of 2013, one year after the publication of European guidelines.
41
42
43
44
45
46

47 We also found a high variability between hospitals in the adherence to guidelines
48
49 when recommending DAPT for at least 12 months which leads to substantial
50
51 differences between hospitals in the rate of patients persisting with the recommended
52
53 DAPT. The progressive increase in the overall rate of 12-months persistence was
54
55 accompanied by a substantial reduction of interhospital variability.
56
57
58
59
60

1
2
3 Likelihood of patients persisting with DAPT for one year is strongly related to the
4
5 instructions given at the PCI hospital discharge, as we observed a lower rate of 12-
6
7 month persistence in patients receiving a discharge DAPT recommendation for less
8
9 than 12 months. Although a causal direct relationship between the established
10
11 recommendation in the more specialised setting and the final prescription at the
12
13 primary care setting cannot be stated on the basis of observational data, this finding
14
15 suggests that prescribing physicians strongly rely on the first recommendation
16
17 specified at the discharge report in the PCI hospital. Therefore, hospital cardiologists
18
19 should be kept aware of their impact and encouraged to be clear and specific enough
20
21 when providing DAPT time recommendations in the discharge report form.
22
23
24
25
26
27
28
29

30 The recommendation in clinical guidelines of DAPT for at least 12 months following
31
32 STEACS[1,2] was based on the duration of follow up of randomised clinical trials
33
34 designed for other purposes[11–13] and, although a 12-month treatment seemed
35
36 reasonable [14], no randomized studies had been performed within the study period
37
38 aimed specifically at comparing 12 months DAPT with shorter periods in STEACS
39
40 patients receiving PCI and thus this recommendation might well be seen as somehow
41
42 arbitrary by some prescribers.
43
44
45
46
47
48
49

50 In 2015 the need for long term DAPT was reinforced by the recommendation of
51
52 extended DAPT beyond 12 months in patients with ACS receiving drug eluting
53
54 stents[15–17], but still safety concerns might induce some prescribers to be reluctant
55
56 to prolong DAPT, especially in patients with higher complexity[18]. Safety concerns
57
58 might also explain the high proportion of discharge reports with non-specified DAPT
59
60

1
2
3 period, which deserved special attention in our analyses. Cardiologists might be
4
5 reluctant to prescribe a specific duration of DAPT maybe fearing about the emergency
6
7 of events that increase the haemorrhagic risk at some point after discharge, thus
8
9 relying on the follow up that will be made at the ambulatory setting. Our results
10
11 showing a high degree of persistence for patients without a specification of DAPT time
12
13 point out to the fact that this decision is not necessarily “incorrect”, and that health
14
15 providers coming later in the process of care are probably doing their job.
16
17
18
19
20
21
22

23 We might wonder whether the observed high variability between hospitals in the
24
25 instructions provided about DAPT duration actually reflects suboptimal quality of care
26
27 or confusion in the interpretation of international guidelines. In fact, although 2012
28
29 ESC guidelines state that DAPT must be continued for 12 months after STEACS with a
30
31 class of recommendation I, the level of evidence was established as C[1]. Thus, there
32
33 was general agreement that a minimum of 12 months of DAPT is likely to be beneficial
34
35 but based only on a consensus of experts or observational studies. Moreover, it is
36
37 literally stated that the given recommendation on DAPT duration should be “with a
38
39 strict minimum of 1 month for patients receiving BMS and 6 months for patients
40
41 receiving DES”, with Class IC and IIb respectively. These messages, which ultimately
42
43 reflected the lack of clinical trials aimed to answer the specific question about DAPT
44
45 duration, could have induced a perception of arbitrariness leading to variability in
46
47 clinical practice.
48
49
50
51
52
53
54
55
56

57 In fact, the optimal duration of DAPT has not yet been totally established in more
58
59 contemporary clinical trials. The most recent randomized clinical trial conducted in
60

1
2
3 patients with STEACS aimed to assess the question of 12-month vs a 6-month DAPT
4
5 duration, showed that 6-month DAPT duration after primary PCI was non-inferior to
6
7 12-month duration to prevent major cardiovascular events[19]. In another trial in the
8
9 context of ACS, 12 months or longer DAPT duration versus 6 months was not
10
11 associated with lower major cardiovascular events and total mortality[20].
12
13
14
15
16

17
18 Regardless the level of the evidence, one would expect that a Class I recommendation
19
20 should be uniformly followed by clinicians. Moreover, as patient characteristics did not
21
22 substantially differed across hospitals, we should expect a lower variability between
23
24 hospitals. A large variation in individual country practices concerning the pattern of
25
26 DAPT duration after ACS has been described, suggesting that local systems are strong
27
28 drivers of DAPT duration[21]. These findings may imply that there is still room for
29
30 improvement in the quality of care of STEACS patients and that quality improvement
31
32 programs, whose efficacy and cost-effectiveness are still under evaluation, could be
33
34 useful to reduce variability in clinical practice[22]. This is of prime importance in the
35
36 context of the prescription of DAPT duration after ACS in which the clinician-driven
37
38 variability in prescription patterns adds to the different levels patients' adherence[21].
39
40 Higher atherosclerotic burden and increased ischemic risk was associated to better
41
42 persistence with DAPT. The need for 12-month DAPT schedules in patients treated
43
44 with drug eluting stents is clearly perceived by physicians but the magnitude of this
45
46 association varies largely between hospitals. This means that, even in clear indications,
47
48 there are different levels of adoption of emerging clinical recommendations in
49
50 hospitals belonging to the same AMI network.
51
52
53
54
55
56
57
58
59
60

1
2
3 It is also apparent from our data that the speed of adoption of clinical guidelines is
4
5 different among hospitals and that an acceptable and generalised level of adherence is
6
7 only reached after two years of implementation. Similar trends have been found in
8
9 other contexts and earlier periods[23–28] reporting DAPT use between 60-80% at
10
11 discharge and between 25-75 % at one year. In this sense, together with other quality
12
13 improvement initiatives, the use of population-based registries to provide audit and
14
15 feedback could be useful to promote quicker and smoother adoption of clinical
16
17 practice guidelines[29].
18
19
20
21
22
23
24

25 There are a number of assumptions that might be questionable: A number of factors
26
27 have been described to contribute to underprescription[30]. The complete process of
28
29 care and the definite prescription at the ambulatory setting is poorly known for
30
31 individual patients and has not been considered in this study. Changes in treatment
32
33 prescription might be justified by the patients' varying conditions during follow up. We
34
35 assume that hospital recommendation influences final prescription, and consequently,
36
37 final adherence to guidelines, but it can also be that both "prescribers" facing the same
38
39 patient share the same criteria for prescription. I.e. the hospital cardiologist might
40
41 have decided to recommend DAPT for a shorter period to an elderly patient with other
42
43 comorbidities and suboptimal quality of life due to mild digestive symptoms, even if
44
45 her objective bleeding risk is not high; similarly, the primary physician or the
46
47 cardiologist at the primary care setting might have also decided to be less aggressive
48
49 for the same reasons, even without being influenced by the recommendation of the
50
51 first prescriber. This would probably explain a large amount of the strong relationship
52
53 between hospital recommendation and pharmacy dispensation. Moreover, although
54
55
56
57
58
59
60

1
2
3 effects were adjusted for patient characteristics and vascular events during follow up,
4
5 there might be other unmeasured reasons for deciding upon a shorter DAPT period
6
7
8 facing an individual patient.
9

10
11
12 In addition, the recommendation at PCI hospital discharge may not coincide with the
13
14 final hospital prescription in patients derived to another reference hospital after PCI.
15
16 However, results of sensitivity analyses excluding these patients did not differ
17
18 substantially from the results of the main analyses.
19
20
21

22
23
24 The study was aimed to ascertain influence of guidelines on hospital recommendation
25
26 and its impact on patients' persistence with DAPT. The impact of persistence on
27
28 clinically relevant results will be assessed in another article. Similarly, the study was
29
30 not specifically aimed at a deep assessment of determinants of adherence. This
31
32 requires a detailed examination of the social context and a detailed assessment of
33
34 individual psychological factors[31].
35
36
37
38
39
40
41

42 **Conclusion**

43
44 The study shows that 12-month DAPT persistence in revascularized patients with
45
46 STEACS in Catalonia (Spain) has substantially increased between years 2010 to 2015
47
48 especially since one year after the publication of European guidelines in 2012.
49
50 Guideline implementation was also followed by a substantial decrease in variability
51
52 between centres. We have shown that instructions given at the PCI hospital discharge
53
54 are strongly associated with persistence. Thus establishing common and rational
55
56 prescribing criteria between hospitals in the STEACS-network may favour patients
57
58
59
60

1
2
3 persistence with scheduled prescriptions and also reduce variability in clinicians'
4
5 practices.
6
7
8
9

10 11 **Author contributions**

12
13
14
15 IFG, AR, JRM conceived and designed the study; AR, JRM and MTF participated in the
16
17 acquisition and analysis of data; HTM, SR, CL, MC, SH, CTQ, JGP, JAGH and MM were
18
19 responsible for data acquisition in their respective hospitals; AR, IFG, JRM, GO, AR, JIP,
20
21 JM and DGD were involved in the interpretation of results; AR and IFG wrote the
22
23 manuscript and all other authors revised it critically and approved its final version
24
25
26
27

28
29 The AMI-Code Registry Investigators (listed below) contribute to the functioning of the
30
31 AMI code and to data acquisition for the AMI-Code Registry:
32
33

34
35 C. Carvajal, P. Martínez, RM. Lidón, J. Bañeras (Hospital Universitari de la Vall
36
37 d'Hebrón, Barcelona), J. Garcia-Picart (Hospital de la Santa Creu i Sant Pau, Barcelona),
38
39 M. Massotti, G. Jiménez, M. Hernández, A. Regueiro (Hospital Clinic, Barcelona), J.
40
41 Basaganyas, P. Loma, M. Cardenas, E. Badosa, A. Fageda (Hospital Josep Trueta,
42
43 Girona) A. Ariza, C. García-Amigó, A. Cequier, A. Gómez-Hospital, G. Marín, J.
44
45 Maristany, V. Montoya (Hospital Universitari de Bellvitge, Hospitalet) , C. Labata, J.
46
47 Mauri, E. Fernández-Nofrerias, X. Carrillo, C. Garcia-Garcia, C. Oliete, (Hospital
48
49 Universitari Germans Trias i Pujol, Badalona) A. Bardaji, G. Bonet-Pineda, S. Rojas
50
51 (Hospital Joan XXIII, Tarragona). Juan F. Muñoz, F. Padilla, S. Homs (Hospital Mútua de
52
53 Terrassa, Terrassa), B. Baquerizo, L. Recasens, H. Tizon-Marcos (Hospital de Mar IMAS,
54
55 Barcelona), A. Bosch Gaya, F. Worner, L. Barta, M. Agustí, A. Gené (Hospital Arnau de
56
57
58
59
60

1
2
3 Vilanova, LLeida), X. Jimenez, A. Mora (Sistema d'Emergencies Mèdiques SEM SA,
4
5 Barcelona), MT. Faixedas, J. Jiménez, A. Rosas (Health Department. Generalitat de
6
7 Catalunya).
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

- 1 Steg PG, James SK, Atar D, *et al.* ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). *Eur Heart J* 2012;**33**:2569–619. doi:10.1093/eurheartj/ehs215
- 2 O’Gara PT, Kushner FG, Ascheim DD, *et al.* 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;**127**:e362–425. doi:10.1161/CIR.0b013e3182742cf6
- 3 Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med* 2005;**353**:487–97. doi:10.1056/NEJMra050100
- 4 Carrillo X, Fernandez-Nofrerias E, Rodriguez-Leor O, *et al.* Early ST elevation myocardial infarction in non-capable percutaneous coronary intervention centres: *in situ* fibrinolysis vs. percutaneous coronary intervention transfer. *Eur Heart J* 2016;**37**:1034–40. doi:10.1093/eurheartj/ehv619
- 5 Regueiro A, Bosch J, Martín-Yuste V, *et al.* Cost-effectiveness of a European ST-segment elevation myocardial infarction network: results from the Catalan Codi Infart network. *BMJ Open* 2015;**5**:e009148. doi:10.1136/bmjopen-2015-009148
- 6 Swieczkowski D, Mogielnicki M, Cwalina N, *et al.* Medication adherence in patients after percutaneous coronary intervention due to acute myocardial infarction: From research to clinical implications. *Cardiol J* 2016;**23**:483–90.

- 1
2
3 doi:10.5603/CJ.a2016.0048
4
5
6 7 Gislason GH, Rasmussen JN, Abildstrøm SZ, *et al.* Long-term compliance with
7
8 beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute
9
10 myocardial infarction. *Eur Heart J* 2006;**27**:1153–8.
11
12 doi:10.1093/eurheartj/ehi705
13
14
15 8 Kontopantelis E, Doran T, Springate DA, *et al.* Regression based quasi-
16
17 experimental approach when randomisation is not an option: Interrupted time
18
19 series analysis. *BMJ* Published Online First: 2015. doi:10.1136/bmj.h2750
20
21
22 9 Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the
23
24 evaluation of public health interventions: A tutorial. *Int J Epidemiol* Published
25
26 Online First: 2017. doi:10.1093/ije/dyw098
27
28
29
30 10 Yeh RW, Secemsky EA, Kereiakes DJ, *et al.* Development and Validation of a
31
32 Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year
33
34 After Percutaneous Coronary Intervention. *JAMA* 2016;**315**:1735.
35
36 doi:10.1001/jama.2016.3775
37
38
39
40 11 Yusuf S, Zhao F, Mehta SR, *et al.* Effects of Clopidogrel in Addition to Aspirin in
41
42 Patients with Acute Coronary Syndromes without ST-Segment Elevation. *N Engl J*
43
44 *Med* 2001;**345**:494–502. doi:10.1056/NEJMoa010746
45
46
47 12 Wiviott SD, Braunwald E, McCabe CH, *et al.* Prasugrel versus Clopidogrel in
48
49 Patients with Acute Coronary Syndromes. *N Engl J Med* 2007;**357**:2001–15.
50
51 doi:10.1056/NEJMoa0706482
52
53
54 13 Wallentin L, Becker RC, Budaj A, *et al.* Ticagrelor versus Clopidogrel in Patients
55
56 with Acute Coronary Syndromes. *N Engl J Med* 2009;**361**:1045–57.
57
58 doi:10.1056/NEJMoa0904327
59
60

- 1
2
3 14 Eisenstein EL, Anstrom KJ, Kong DF, *et al.* Clopidogrel Use and Long-term Clinical
4
5 Outcomes After Drug-Eluting Stent Implantation. *JAMA* 2007;**297**:159.
6
7
8 doi:10.1001/jama.297.2.joc60179
9
- 10 15 Bonaca MP, Bhatt DL, Cohen M, *et al.* Long-Term Use of Ticagrelor in Patients
11
12 with Prior Myocardial Infarction. *N Engl J Med* 2015;**372**:1791–800.
13
14
15 doi:10.1056/NEJMoa1500857
16
- 17 16 Mauri L, Kereiakes DJ, Yeh RW, *et al.* Twelve or 30 Months of Dual Antiplatelet
18
19 Therapy after Drug-Eluting Stents. *N Engl J Med* 2014;**371**:2155–66.
20
21
22 doi:10.1056/NEJMoa1409312
23
- 24 17 Levine GN, Bates ER, Bittl JA, *et al.* 2016 ACC/AHA Guideline Focused Update on
25
26 Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease:
27
28 A Report of the American College of Cardiology/American Heart Association
29
30 Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2016;**68**:1082–115.
31
32
33 doi:10.1016/j.jacc.2016.03.513
34
- 35 18 Tinetti ME, Bogardus ST, Agostini J V. Potential Pitfalls of Disease-Specific
36
37 Guidelines for Patients with Multiple Conditions. *N Engl J Med* 2004;**351**:2870–
38
39 4. doi:10.1056/NEJMsb042458
40
41
42
43
- 44 19 Kedhi E, Fabris E, van der Ent M, *et al.* Six months versus 12 months dual
45
46 antiplatelet therapy after drug-eluting stent implantation in ST-elevation
47
48 myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority
49
50 trial. *BMJ* 2018;**363**:k3793. doi:10.1136/bmj.k3793
51
52
53
- 54 20 Hahn J-Y, Song Y Bin, Oh J-H, *et al.* 6-month versus 12-month or longer dual
55
56 antiplatelet therapy after percutaneous coronary intervention in patients with
57
58 acute coronary syndrome (SMART-DATE): a randomised, open-label, non-
59
60

- 1
2
3 inferiority trial. *Lancet* 2018;**391**:1274–84. doi:10.1016/S0140-6736(18)30493-8
4
5
6 21 Bueno H, Pocock S, Danchin N, *et al.* International patterns of dual antiplatelet
7
8 therapy duration after acute coronary syndromes. *Heart* 2017;**103**:132–8.
9
10 doi:10.1136/heartjnl-2016-309509
11
12
13 22 Flather MD, Babalis D, Booth J, *et al.* Cluster-randomized trial to evaluate the
14
15 effects of a quality improvement program on management of non–ST-elevation
16
17 acute coronary syndromes: The European Quality Improvement Programme for
18
19 Acute Coronary Syndromes (EQUIP-ACS). *Am Heart J* 2011;**162**:700–707.e1.
20
21
22 doi:10.1016/j.ahj.2011.07.027
23
24
25 23 Czarny MJ, Nathan AS, Yeh RW, *et al.* Adherence to Dual Antiplatelet Therapy
26
27 After Coronary Stenting: A Systematic Review. *Clin Cardiol* 2014;**37**:505–13.
28
29
30 doi:10.1002/clc.22289
31
32
33 24 Green A, Pottegård A, Broe A, *et al.* Initiation and persistence with dual
34
35 antiplatelet therapy after acute myocardial infarction: A Danish nationwide
36
37 population-based cohort study. *BMJ Open* 2016;**6**. doi:10.1136/bmjopen-2015-
38
39 010880
40
41
42 25 Anastasius M, Lau JK, Hyun K, *et al.* The underutilisation of dual antiplatelet
43
44 therapy in acute coronary syndrome. *Int J Cardiol* 2017;**240**:30–6.
45
46
47 doi:10.1016/j.ijcard.2017.04.077
48
49
50 26 Prami T, Khanfir H, Deleskog A, *et al.* Clinical factors associated with initiation of
51
52 and persistence with ADP receptor-inhibiting oral antiplatelet treatment after
53
54 acute coronary syndrome: a nationwide cohort study from Finland. *BMJ Open*
55
56 2016;**6**:e012604. doi:10.1136/bmjopen-2016-012604
57
58
59 27 Varenhorst C, Jensevik K, Jernberg T, *et al.* Duration of dual antiplatelet
60

- 1
2
3 treatment with clopidogrel and aspirin in patients with acute coronary
4
5 syndrome. *Eur Heart J* 2014;**35**:969–78. doi:10.1093/eurheartj/eh438
6
7
- 8 28 Chung S-C, Sundström J, Gale CP, *et al.* Comparison of hospital variation in acute
9
10 myocardial infarction care and outcome between Sweden and United Kingdom:
11
12 population based cohort study using nationwide clinical registries. *Br Med J*
13
14 2015;**351**:h3913. doi:10.1136/BMJ.H3913
15
16
- 17 29 Eisenstein EL, Wojdyla D, Anstrom KJ, *et al.* Evaluating the impact of public
18
19 health notification: Duke clopidogrel experience. *Circ Cardiovasc Qual Outcomes*
20
21 2012;**5**:767–74. doi:10.1161/CIRCOUTCOMES.111.963330
22
23
24
- 25 30 Cabana MD, Rand CS, Powe NR, *et al.* Why don't physicians follow clinical
26
27 practice guidelines? A framework for improvement. *JAMA* 1999;**282**:1458–
28
29 65.<http://www.ncbi.nlm.nih.gov/pubmed/10535437> (accessed 28 Nov 2017).
30
31
- 32 31 Ferreira-Gonzalez I, Marsal JR, Ribera A, *et al.* Background, Incidence, and
33
34 Predictors of Antiplatelet Therapy Discontinuation During the First Year After
35
36 Drug-Eluting Stent Implantation. *Circulation* 2010;**122**:1017–25.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Patients flow

Figure 2. Observed proportion of patients persisting with DAPT for at least 12 months at each quarter and the interrupted time series model fitted after setting a one year lag period from publication to implementation of guidelines.

Figure 3. Temporal trend of interhospital variability in 12 months DAPT recommendation at the PCI hospital, measured as the percentage of variance explained by the hospital level (intraclass correlation and 95 % CI). Vertical dashed line indicates publication of guidelines.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Patients flow
190x254mm (96 x 96 DPI)




Figure 2. Observed 12-months persistence rate by quarter and interrupted time series model specification after setting a one year lag period for guidelines implementation

127x127mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Predicted probabilities of 12-months persistence by (A) drug eluting stent, (B) recommendation pattern and (C) center, over time

127x304mm (300 x 300 DPI)

Supplemental methods

Data validation processes in the AMI Code registry

1. Automatic data validation processes to identify and feed-back missing data and incongruities.

2. Periodic data validation process every 3-6 months:

Since year 2011 this process was automated. The system automatically detects missing information in key variables and the identification of AMI codes that were activated by the emergency services (before admission) and were not included in the registry. Feed back for data validation is sent every 3-6 months for amendment or justification to the person responsible for data entry at each AMI Code Hospital.

Since year 2015 the automated process can be managed directly at any time by the person responsible for data entry in each hospital.

3. Specific studies:

In 2012 data were evaluated for **exhaustiveness**: all AMI cases consecutively admitted in 43 hospitals in Catalonia (10 AMI Code hospitals and 32 no AMI Code hospitals) during a 3 months period were registered and compared with the episodes registered in the AMI Code registry.

Between 88-92% of STEACS episodes were included in the AMI Code registry.

In 2013 concordance of the information between the AMI Code registry and the information from clinical records was assessed. 330 cases were analyzed and concordance was good for all key variables and there were no differences between hospitals.

1 **Supplemental tables**

2
3
4 Supplemental table 1. ICD9 codes used for the identification of conditions and diseases present at index
5
6 admission and for the identification of events during follow up.

7
8
9

Disease or condition	ICD9 diagnostic or procedure code
Heart failure	428.0, 428.1, 428.22, 428.23, 428.3, 428.32, 428.33, 428.41, 428.43
Renal disease	585*
Neoplasia	140-239
Anemia	280-285
Chronic obstructive pulmonary disease	491-492, 494*, 496*
Peripheral arterial disease	440.2, 440.3, 440.4
Atrial fibrillation	427.3*
Events during follow up	
Acute myocardial infarction	410*, except: 410.*2
Ischemic stroke	433*, 434*, except: 433.*0, 434.*0
Haemorrhagic stroke	430*, 431*, 432*
Intraocular bleeding	362.81, 363.6, 363.61, 363.62, 376.32, 377.42, 379.23
Digestive bleeding	530.21, 530.7, 530.82, 531.0, 531.2, 531.4, 531.6, 532.0, 532.2, 532.4, 532.6, 533.0, 533.2, 533.4, 534.4, 534.6, 535.01, 535.11, 535.21, 535.31, 535.41, 535.51, 535.61, 535.71, 537.83, 562.02, 562.03, 562.12, 562.13, 569.3, 569.85, 578.1, 578.9
Other bleeding	246.3, 459.0, 602.1, 784.8, 596.7, 599.7, 852*, 997.02, 998.1,
Endoscopic treatment	444.3, 454.2, 454.3
Transfusion	990.4

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Supplemental table 2. ATC codes used for the identification of drug treatment

Drug treatment	ATC code
ASA	B01AC06, N02BA01, B01AC30
Ticlopidine	B01AC05
Clopidogrel	B01AC04
Prasugrel	B01AC22
Ticagrelor	B01AC24
Dabigatran etexilate	B01AE07
Rivaroxaban	B01AF01
Apixaban	B01AF02
Beta-blocker	C07
ACE inhibitor	C09
Statins	C10AA


Supplemental table 3. Factors associated with a persistence of at least 12 months as assessed with interrupted time series logistic regression model. Results of sensitivity analyses.

Fixed Effects	Original Model			Discharged home			Non-ischemic or haemorrhagic events		
	OR	CI95%	P value	OR	CI95%	P value	OR	CI95%	P value
Drug eluting stent	1.90	1.50 - 2.40	<0.001	2.00	1.43 - 2.81	<0.001	1.92	1.54 - 2.39	<0.001
Number of Stents	1.22	1.13 - 1.32	<0.001	1.10	0.98 - 1.24	0.117	1.24	1.15 - 1.35	<0.001
Antiplatelet agent at discharge (Ref. Clopidogrel)									
Prasugrelor	1.59	0.88 - 1.26	<0.001	1.72	1.34 - 2.20	<0.001	1.63	1.38 - 1.91	<0.001
Ticagrelor	1.05	1.36 - 1.86	0.575	1.06	0.81 - 1.38	0.665	1.05	0.87 - 1.27	0.614
Recommendation at PCI hospital discharge (Ref. 1 month)									
<12 months	1.67	0.89 - 3.14	0.110	0.98	0.51 - 1.88	0.957	2.03	0.97 - 4.24	0.059
≥ 12 months	5.76	3.26 - 10.2	<0.001	4.29	2.45 - 7.51	<0.001	7.22	4.09 - 12.8	<0.001
unknown	2.25	0.84 - 6.01	0.107	2.81	1.33 - 5.93	0.007	2.62	0.95 - 7.24	0.064
Hyperlipidemia	1.19	1.08 - 1.31	<0.001	1.25	1.09 - 1.44	0.002	1.22	1.11 - 1.35	<0.001
Previous by-pass surgery	1.85	1.09 - 3.14	0.023	1.11	0.51 - 2.41	0.795	1.91	1.05 - 3.46	0.033
Two or more treated vessels	1.21	1.10 - 1.33	<0.001	1.27	1.10 - 1.46	0.001	1.12	1.01 - 1.24	0.026
Drug eluting stents * Time (quarter)	0.96	0.94 - 0.97	<0.001	0.97	0.94 - 0.99	0.006	0.96	0.94 - 0.97	<0.001
Guidelines implementation	1.20	1.11 - 1.30	<0.001	1.10	0.96 - 1.26	0.161	1.23	1.14 - 1.34	<0.001
Recommendation at PCI hospital discharge (Ref. 1 month) * Time (quarter)*Guidelines implementation									
<12 months	0.90	0.79 - 1.04	0.144	1.03	0.82 - 1.28	0.806	0.89	0.78 - 1.03	0.118
≥12 months	0.86	0.79 - 0.94	<0.001	0.93	0.81 - 1.08	0.349	0.84	0.77 - 0.92	<0.001
unknown	0.88	0.81 - 0.97	0.007	0.97	0.84 - 1.12	0.678	0.86	0.78 - 0.94	0.001
Random Effects	Var.	95% CI		Var.	95% CI		Var.	95% CI	
Random - Intercept	0.46	0.22 - 1.53		0.26	0.12 - 0.88		0.40	0.19 - 1.32	
Random - Slopes									
Recommendation at PCI hospital discharge (Ref. 1 month)									
<12 months	0.37	0.17 - 1.23		0.15	0.07 - 0.49		0.64	0.31 - 2.15	
≥12 months	0.39	0.19 - 1.31		0.30	0.14 - 0.99		0.40	0.19 - 1.33	
unknown	1.97	0.93 - 6.58		0.66	0.31 - 2.18		2.09	0.99 - 6.97	
Drug eluting stent	0.10	0.05 - 0.33		0.17	0.08 - 0.57		0.08	0.04 - 0.26	
ICC	0.085			0.043			0.098		

Supplemental figure 1. Persistence with DAPT from discharge to 12 months by year of episode.




Supplemental figure 2. Antiplatelet agent taken at discharge by quarter of the index episode.



Peer review only

Supplemental figure 3. DAPT duration recommended in each hospital by year of episode



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page num
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3 (Design)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	7-8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	10-11
Study size	10	Explain how the study size was arrived at	9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	10-11 10-11 13 13 12
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	12 12 Fig 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	Tables 1, 2 Tables 1, 2 8
Outcome data	15*	Report numbers of outcome events or summary measures over time	Fig 1

suppl

1			suppl
2	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted
3			estimates and their precision (eg, 95% confidence interval). Make
4			clear which confounders were adjusted for and why they were
5			included
6			
7			(b) Report category boundaries when continuous variables were
8			categorized
9			
10			(c) If relevant, consider translating estimates of relative risk into
11			absolute risk for a meaningful time period
12	Other analyses	17	Report other analyses done—eg analyses of subgroups and
13			interactions, and sensitivity analyses
14			Table 3 suppl
15	Discussion		
16	Key results	18	Summarise key results with reference to study objectives
17			15
18	Limitations	19	Discuss limitations of the study, taking into account sources of
19			potential bias or imprecision. Discuss both direction and magnitude of
20			any potential bias
21			
22	Interpretation	20	Give a cautious overall interpretation of results considering
23			objectives, limitations, multiplicity of analyses, results from similar
24			studies, and other relevant evidence
25			19-20
26	Generalisability	21	Discuss the generalisability (external validity) of the study results
27			20
28	Other information		
29	Funding	22	Give the source of funding and the role of the funders for the present
30			study and, if applicable, for the original study on which the present
31			article is based
32			5

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.